



Infection Prevention High Stakes Higher Standards Welcome!

APIC New England Spring Conference
Friday May 1, 2026 | Springfield, MA



 **APIC** NEW ENGLAND





APIC New England Chapter Updates

Membership Update

- Total active members: 411
- New to the profession: 99 members (24%)
- CIC certified: 178 members (43%)
- LTC-CIP certified: 5 members (1.2%)

Nominating & Awards Committee Update

Congratulations

- Karen Miller- In Person APIC National Conference
- Laurie Trezza & Aminat-Alarape-Raji- Virtual APIC National Conference
- Abegail Pangan- First Place Shirley Bradley Award
- Manju Matthew- Second Place Shirley Bradley Award

Agenda Highlights

Agenda Topics

- Surgical Prophylaxis
- Applying ASHRAE Guideline 43 to Empower IPs to Strengthen Ventilation-Based Infection Prevention
- Measles
- Project Management
- Legionella: The Silent Killer

Biography: Rebecca Wang, MD

Rebecca is an Infectious Disease physician at Dartmouth Hitchcock Medical Center. She received her MD from Geisel School of Medicine at Dartmouth. She went on to complete her Internal Medicine residency and Infectious Diseases fellowship at the Hospital of the University of Pennsylvania. She joined as faculty at Dartmouth Hitchcock Medical Center in 2021. She has training and interest in antimicrobial stewardship as well as quality improvement, and she currently serves as Co-Director of the Antimicrobial Stewardship program.



Peri-Operative Antibiotic Prophylaxis

Rebecca Wang, MD

Co-Director of Antimicrobial Stewardship Program

Dartmouth-Hitchcock Medical Center



Financial Disclosures

I have no financial disclosures.


Objectives

- 1) Review peri-operative antibiotic selection and administration for prevention of surgical site infection
- 2) Discuss antibiotic allergies in the context of peri-operative antibiotic selection
- 3) Discuss adjunctive strategies to prevent surgical site infection
- 4) Highlight areas of collaboration between antimicrobial stewardship, infection prevention, and other quality champions

Definition of Antimicrobial Stewardship

“Coordinated interventions designed to improve and measure the **appropriate use of antimicrobials** by promoting the selection of the optimal **drug regimen, dose, duration of therapy, and route of administration.**”

- Consensus statement from IDSA, SHEA, and PIDS



Common Areas of IPP/ASP Collaboration

IPP Focus	ASP Collaboration	Shared Goal
Catheter-associated urinary tract infection (CAUTI)	- Diagnostic stewardship for urine testing - Education regarding asymptomatic bacteriuria	- Decrease unnecessary antibiotic prescribing - Decrease CAUTI rates
<i>C. difficile</i> infection (CDI)	- Diagnostic stewardship for <i>C. difficile</i> testing - Optimization of <i>C. difficile</i> treatment and prophylaxis - Optimization of high-risk antibiotic use	- Decrease unnecessary antibiotic prescribing - Decreased CDI rates
Surgical site infection (SSI)	- Creation of institutional peri-operative antibiotic prophylaxis guideline	- Optimize peri-operative antibiotic administration - Decrease SSI rates

Surgical Site Infections (SSIs)

- Occur in ~1-3% of patients undergoing surgery at acute care hospitals, depending on procedure type
- Associated with negative downstream consequences, including...
 - Increased length of stay
 - Increased rates of re-operation
 - Increased attributable mortality
- One of the most costly HAIs, contributing to ~\$3.5 to 10 billion in healthcare expenditure annually
- **Up to 60% are preventable using evidence-based guidelines**

Principles of Antibiotic Prophylaxis

Chosen antibiotics(s) should be...

- 1 Active against pathogen(s) most likely to contaminate surgical site
- 2 Given at an appropriate time and dose to ensure adequate serum concentrations during time of potential contamination
- 3 Administered for shortest effective period of time, to minimize adverse effects and development of antimicrobial resistance

Antibiotic Selection

Procedure Type	Implicated Pathogens	Preferred Therapy
Clean (Uninfected wound, no viscus entered)	<u>Skin pathogens:</u> <i>S. aureus</i> , coagulase-negative Staphylococci, Streptococci	Cefazolin
Clean-contaminated (Uninfected wound, viscus entered under controlled circumstances)	<u>Skin pathogens:</u> <i>S. aureus</i> , coagulase-negative Staphylococci, Streptococci <u>GI pathogens:</u> Enteric Gram-negative rods (e.g., <i>E coli</i> , <i>Klesbiella</i> spp.), Enterococci, GI anaerobes	Cefazolin* +/- Metronidazole *Depending on local resistance rates, consider substituting a beta- lactam with “broader” Gram- negative coverage, such as ceftriaxone



Dartmouth Health

Organisms


Per CLSI guidelines, there should be 30 or more isolates to be considered statistically adequate for selecting antibiotics for treatment.

	Number of Isolates	Penicillin	Ampicillin	Ox/Nafcillin	Ampicillin/Sulbactam	Piperacillin/Tazo	Cefazolin (first)	Cefuroxime (second)	CeftAZidime (third)	CefTRIaxone (third)	Cefepime (fourth)	Meropenem	Daptomycin	Linezolid	Gentamicin	Tobramycin	Vancomycin
GRAM POSITIVES																	
<i>Staphylococcus aureus</i> - ALL ¹	861			61			61						100	100	100 ²		100
- <i>Staphylococcus aureus</i> - MSSA	526			100			100						99	100	100 ²		100
- <i>Staphylococcus aureus</i> - MRSA	335			0			0						100 ³	100	100 ²		100
<i>Staphylococcus lugdunensis</i>	41			93			93							100	100 ²		100
<i>Staphylococcus coagulase negative</i> sp.	153			47			47						100	100	92 ²		100
<i>Streptococcus pneumoniae</i>	34	77								97		91					100
- <i>Streptococcus pneumoniae</i> (meningitis)	34	76								97							
<i>Enterococcus faecium</i>	47	19	19				0	0	0	0	0		93 ^{3,4}	100	96 ^{2,5}		28
<i>Enterococcus faecalis</i>	101	100	100				0	0	0	0	0		100 ³	100	85 ^{2,5}		97
<i>Strep. anginosus</i> grp (<i>S. milleri</i>)	72	100 ⁶								100 ⁶							
<i>Cutibacterium acnes</i>	36	100										100					
GRAM NEGATIVES																	
<i>Haemophilus influenzae</i>	54		74 ⁷														
<i>Escherichia coli</i>	280		62 ⁸		69	94	86 ⁸	88 ⁸	91 ⁹	87	90	100			92	92 ⁹	
<i>Enterobacter cloacae</i> complex	71		0			81	0		77 ⁹	70	88	100			96	92 ⁹	
<i>Klebsiella oxytoca</i>	39		0		77	90				90	100	100			100		
<i>Klebsiella pneumoniae</i>	109		0		79	94	90 ⁸	87 ⁸	86 ⁹	87	85	99			97	90 ⁹	
<i>Proteus mirabilis</i>	44				89	98			98 ⁹	96		100			91	95 ⁹	
<i>Pseudomonas aeruginosa</i>	163		0			85			82		80	95				98	

Cefazolin

- Most widely studied antibiotic for peri-operative prophylaxis, with proven efficacy
- Has a desirable spectrum of activity against commonly encountered pathogens
 - Including enteric Gram-negative rods, such as *E. coli* and *Klebsiella* spp.
- Has a R1 side chain that is distinct from all penicillins and all other cephalosporins (except ceftazidime)
 - Safe to use in the context of many beta-lactam allergies
- **Preferred prophylactic antibiotic for many procedure types**

Beta-Lactam Allergy



Penicillin allergy associated with:

- Increased use of alternatives to beta-lactams
- Increased rates of surgical site infection
- Increased rates of *C. difficile* infection
- Increased rates of MRSA colonization and other antimicrobial resistance
- Increased length of stay
- Increased cost to hospital systems

Cefazolin in Beta-Lactam Allergy

- Recent meta-analysis¹ shows rates of dual allergy to penicillin and cefazolin to be as low as...
 - **Less than 1% for patients without a “confirmed” penicillin allergy** (e.g., positive skin test)
 - ~3% for patients with a confirmed penicillin allergy
- Updated American Academy of Allergy, Asthma, and Immunology (AAAAI) practice parameter² endorses use of cefazolin for patients with a history of anaphylaxis to penicillin, **without any need for additional testing or precautions**
 - No need for skin tests or test doses, decreasing logistical barriers

¹JAMA Surg. 2021 Apr 1;156(4):e210021.

²J Allergy Clin Immunol. 2022 Dec;150(6):1333-1393.


Beta-Lactam vs. Alternative Prophylaxis for Elective Colorectal Surgery

Retrospective cohort study of elective colectomy cases from an institutional QI database


Number of SSIs

- Beta-lactam: 571 (6.3%)
- Non-beta-lactam: 51 (9.5%)

Adjusted OR for SSI associated with use of a non-beta-lactam antibiotic was **1.65** ($p < 0.01$)




Beta-Lactam Allergy Assessment



Promoting Cefazolin Prophylaxis in Patients with Reported Penicillin Allergy

- Surgical prophylaxis guideline updated in 2022, expanding use criteria for cefazolin in those with penicillin allergy
- Pre- and post-intervention study sought to assess the impact of this update



Promoting Cefazolin Prophylaxis in Patients with Reported Penicillin Allergy

*Adjusted OR for cefazolin use = **1.87** (95% CI 1.67-2.10)

TABLE III. Outcomes of patients with penicillin allergy labels undergoing surgery before and after the updated surgical guideline implementation

Outcomes	Before guideline release (n = 3085)	After guideline release (n = 4102)	P value
No. of antibiotics received, mean $\pm$ SD	1.5 $\pm$ 0.9	1.5 $\pm$ 1.0	.294
Medication administration, n (%)			
Cefazolin	2256 (73.2)	3390 (82.6)	<.001
Vancomycin	273 (8.9)	330 (8.0)	.223
Clindamycin	444 (14.4)	350 (8.5)	<.001
Gentamicin	482 (15.6)	313 (7.6)	<.001
Safety outcomes, n (%)			
Anaphylaxis	0 (0)	1 (0.02)	1.000

Non-Beta-Lactam Alternatives

Procedure Type	Implicated Pathogens	Preferred Therapy	Alternative Therapy
Clean (Uninfected wound, no viscus entered)	Skin	Cefazolin	Vancomycin (Or Clindamycin)
Clean-contaminated (Uninfected wound, viscus entered under controlled circumstances)	Skin, GI	Cefazolin* + Metronidazole *Depending on local resistance rates, consider substituting a beta-lactam with “broader” Gram-negative coverage, such as ceftriaxone	Levofloxacin + Metronidazole

Dosing + Intra-Operative Redosing

- Initial antibiotic dose should be administered at a time to provide serum and tissue concentrations that exceed MICs for the probable organisms at the time of incision
- Intra-operative redosing is needed if duration of the procedure exceeds two half-lives of the antibiotic
- Earlier redosing of most antibiotics is needed if there is excessive intra-operative blood loss (i.e., >1500 mL)

Dosing + Intra-Operative Redosing

Antibiotic	Dose	Infusion Time	Pre-Operative Dose (Prior to Incision)	Intra-Operative Redosing Interval
Cefazolin	2g if <120 kg 3g if ≥120 kg*	5-30 min	Within 60 min	CrCl ≥20: Q4h CrCl <20: Q6h
Ceftriaxone	2g	5-30 min	Within 60 min	Q12h
Clindamycin	900 mg	30 min	Within 60 min	Q6h
Levofloxacin	500 mg	60 min	Within 120 min	CrCl ≥20: Q12h CrCl <20: None
Metronidazole	500 mg	30 min	Within 60 min	Q12h
Vancomycin	15 mg/kg	Variable	Within 120 min	None

*Recent meta-analysis remarks on a lack of need for obesity dosing [Anesthesiology. 2025 May 1;142(5):929-948]. Guidelines have not yet been updated, and adoption into clinical practice has been variable.

Antibiotic Timing vs. SSI Risk

TABLE 3. Association Between Timing of Prophylaxis and Infection Risk

Timing Interval Relative to Incision	Infection/N-at-Risk	Infection Risk*	Unadjusted Relative Risk of Infection (95% CI)	Adjusted Risk Odds Ratio for Infection From Conditional Logistic Regression (95% CI) [†]
Group 1: Vancomycin/fluoroquinolones within 60 min or cephalosporins [‡] within 30 min before incision	38/1844	2.1%	Referent Group	Referent Group
Group 2: Vancomycin/fluoroquinolones 61–120 min or cephalosporins [‡] 31–60 min before incision	43/1796	2.4%	1.16 (0.75, 1.79), <i>P</i> = 0.50	1.48 (0.92, 2.38), <i>P</i> = 0.06
Group 3: Any other preincision administration regimen	18/644	2.8%	1.36 (0.78, 2.36), <i>P</i> = 0.28	1.30 (0.70, 2.41), <i>P</i> = 0.39
Group 4: Post-incision	10/188	5.3%	2.58 (1.31, 5.10), <i>P</i> = 0.005	2.20 (1.03, 4.66), <i>P</i> = 0.02

- Trend towards decreased SSI risk when antibiotics were administered closer to time of skin incision, though not statistically significant
- Higher rates of SSI seen if first dose of antibiotic was given AFTER skin incision


Antibiotic Timing vs. SSI Risk

Large cohort study from a national Swiss database, with the following inclusion criteria...

- 1) Undergoing 1 of 11 elective surgical procedures
 - Including knee/hip arthroplasty, laminectomy, spondylodesis, cardiac surgery, colon surgery, cholecystectomy, hernia repair, gastric bypass, Cesarean delivery, hysterectomy
- 2) Surgery occurred between January 2009 and December 2020
- 3) Administration of cefuroxime (with or without metronidazole) in the 120 minutes prior to surgical incision

Antibiotic Timing vs. SSI Risk

Figure 2. Crude Surgical Site Infection (SSI) Rate Relative to Timing of Surgical Antimicrobial Prophylaxis (SAP)



Timing of cefuroxime administration vs. SSI risk

- *0-30 min*: **aOR=0.85** (95% CI 0.78-0.93), $p<0.001$
- *31-60 min*: **aOR=0.91** (95% CI 0.84-0.98), $p=0.01$
- *61-120 min*: Reference

Suggests that “optimal” timing of pre-operative antibiotic administration may be closer to time of skin incision

Antibiotic Duration

- Previous guidelines recommended discontinuation of antibiotics “within 24 hours” of surgery
- Meta-analysis¹ showed no evidence that additional antibiotic doses after incision closure lead to reduced rates of SSI
 - If compliant with timing of initial antibiotic dose and subsequent intra-operative doses
- Updated SHEA compendium² recommends discontinuing antibiotics after incision closure in the operating room
- Antibiotics should NOT be continued due to presence of a drain

¹Lancet Infect Dis. 2020 Oct;20(10):1182-1192.

²Infect Control Hosp Epidemiol. 2023 May;44(5):695-720.

No Antibiotics for Low-Risk Procedures?

- Retrospective review of patients who underwent simple knee arthroscopy between 2007 and 2012
- Looked at SSI rates based on whether antibiotic prophylaxis was given


Table 2. Infections by Antibiotic Status

Category	Antibiotics	No Antibiotics	Total	Risk Ratio	95% Confidence Interval	P Value
No. of study patients (%)	32,836 (80.5)	7,974 (19.5)	40,810 (100)			
Infection (%)	159 (0.48)	43 (0.54)	202 (0.50)	0.90	0.64-1.26	.53
Deep	25 (0.08)	11 (0.14)	36 (0.09)	0.55	0.27-1.12	.10
Superficial	134 (0.41)	32 (0.40)	166 (0.41)	1.01	0.69-1.49	.93
Antibiotic* (%)						
Cefazolin	29,662 (90.3)					
Clindamycin	2,742 (8.4)					
Vancomycin	472 (1.4)					
Other	17 (0.1)					

*57 knee arthroscopies had more than 1 antibiotic given (total = 32,893).

Role of Oral Antibiotics?

- No role as stand-alone prophylaxis
- Have demonstrated benefit when given in addition to IV antibiotics (with or without mechanical bowel preparation), for elective colorectal surgeries



Role of Oral Antibiotics?

Meta-analysis of oral antibiotics (OAB) and/or mechanical bowel prep (MBP) for elective colorectal surgery:

- OAB + MBP was associated with the lowest risk of SSI
 - OAB alone ranked as second best, though data available on this approach was limited
 - No difference between MBP only vs. no adjunctives
- **Endorsed by SHEA as an essential practice for SSI prevention**

Addition of MRSA Coverage?

- Routine MRSA coverage is not needed for antibiotic prophylaxis, regardless of procedure type
- However, may be utilized in select scenarios...
 - Patients known to be MRSA colonized, particularly if implantation of prosthetic material is planned
 - In the setting of proven outbreaks of SSIs due to MRSA
- Preference is to ADD vancomycin to cefazolin, rather than replace
 - Vancomycin has no activity against Gram-negative pathogens and has less potent activity against MSSA than beta-lactams
- Combination prophylaxis increases the risk of adverse events

Combination vs. Single-Agent Prophylaxis


- Retrospective cohort study utilizing VA database (n=20,101)
- **Amongst cardiac surgeries, combination prophylaxis was associated with a significantly lower incidence of SSI**, compared to single agent prophylaxis (0.95% vs. 1.48%, aOR=0.61)
 - Held true for those who were MRSA colonized (NNT=53) and not MRSA colonized (NNT=176)
- No benefit to combination prophylaxis seen for orthopedic, vascular, colorectal, or hysterectomy procedures
- **Higher AKI rates with combination prophylaxis** [23.8%, vs. 20.8% (vancomycin alone) vs. 13.9% (beta-lactam alone)]

Role of *S. Aureus* Decolonization?

- Endorsed as essential practice by SHEA for cardio-thoracic and orthopedic procedures
 - Can be considered for other procedure types involving implantation of prosthetic material
- Published data most supportive of intranasal mupirocin, though there are emerging data on use of intranasal povidone-iodine
 - Latter is logistically easier, as this is applied immediately before surgery
- Universal vs. targeted decolonization are both options, though former may be easier to implement



Should Prophylaxis be Adjusted if Recent Infection or Colonization w/ MDR Organism?



Pathogen

- Organism
- Susceptibilities



Host

- Comorbidities



Procedure

- Extent of surgery
- Proximity of reservoir to incision and operative sites

SSI Prevention in Antibiotic Resistance Era


Stewardship Framework

- 1) Avoid antibiotics in contexts where studies indicate that they are not beneficial
- 2) Consider antimicrobial strategies with lower-risk profiles
- 3) Maximize the effect of antibiotic prophylaxis through more targeted use
- 4) Leverage non-antibiotic SSI prevention measures
- 5) Consider new models of SSI pathogenesis

Creation of a Local Guideline

- 1) Begin with published national guidelines and/or examples from other institutions
- 2) Tailor recommendations to:
 - a) Local antibiotic resistance patterns
 - b) Breakthrough SSIs?
 - c) Practices of local surgeons, as clinically appropriate
- 3) Identify key stakeholder(s) from surgical groups to collaborate and serve as champions
- 4) Do not try to account for every possible clinical scenario
- 5) Incorporate considerations of all sites in health system, as feasible

Defining & Engaging Key Stakeholders



Workgroup & Presentation Forums

Forum	Type	Date
Antimicrobial stewardship committee	System	2/2026
SSI prevention task force	Local	3/2026
Peri-operative quality council	Local	4/2026
Surgical efficiency and quality group	Affiliate	5/2026
Antimicrobial drug and practice specialty panel (of the system pharmacy and therapeutics committee)	System	6/2026

Translating Guidelines into Action

Embed real-time decision support for ordering providers at the point of prescription

☒ Antibiotics to be ordered

☒ Hysterectomy Day of Procedure Antibiotics

☐ ceFAZolin + metroNIDAZOLE intravenous

☒ History of allergic reaction to any beta-lactam drug?

life threatening reaction: Including history of anaphylaxis, throat tightness/trouble breathing, serum sickness, Stevens Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), acute interstitial nephritis, drug-induced hepatitis, Drug Rash Eosinophilia and Systemic Syndrome (DRESS), or hemolytic anemia

☐ Life threatening reaction?

☒ NON-life threatening reaction?

☐ History of reaction to a penicillin?

☒ History of reaction to a cephalosporin OR reaction to BOTH cephalosporin AND penicillin?

☒  Aerobic - gentamicin OR levoFLOXacin

Choose one.

☐ gentamicin (Garamycin)
5 mg/kg/dose (Adjusted), Intravenous, ONCE, On Call to OR Infuse over 60 minutes., Day of Surgery (Day of Procedure)

☐ levoFLOXacin in D5W (Levaquin)
500 mg. Intravenous, ONCE, On Call to OR Infuse over 60 minutes., Day of Surgery (Day of Procedure). Routine

☒  Anaerobic - metroNIDAZOLE OR clindamycin

Choose one

☐ metroNIDAZOLE (Flagyl)
500 mg. Intravenous, ONCE, On Call to OR Infuse over 30 minutes., Day of Surgery (Day of Procedure)

☐ clindamycin (Cleocin)
900 mg. Intravenous, ONCE, On Call to OR Infuse over 30 minutes., Day of Surgery (Day of Procedure)

Thank You 😊

Antimicrobial Stewardship




Julie Ann Justo,
PharmD, MS



Rebecca
Wang, MD



Craig Worby,
PharmD



Michael Calderwood,
MD, MPH



Gabriela Andujar
Vazquez, MD

Quality & Safety

Infection Prevention

Thank You!

Biography: Bryan Connors, MS, CIH, HEM

Bryan Connors directs Environmental Health & Engineering's (EH&E) healthcare practice, which specializes in physical environment-related infection prevention, Joint Commission Environment of Care compliance, and environmental health and safety program management. Bryan is a Certified Industrial Hygienist who has spent his career in healthcare as a direct hospital employee/Industrial Hygienist and consultant for over 25 years. He has led numerous investigations of infection outbreaks and developed proactive programs related to air and water quality matters, working closely with facilities and infection prevention teams.






Applying ASHRAE Guideline 43 to Empower IPs to Strengthen Ventilation-Based Infection Prevention

May 1, 2026

Bryan Connors, M.S., CIH, Managing Principal Consultant, Healthcare, EH&E

What is ASHRAE/ASHE 43?

- Operations Guideline for Ventilation of Health Care Facilities
- Provides clear instructions on operation and maintenance of healthcare facility ventilation systems
 - Acceptable ranges for specific parameters
 - Requires written ventilation management plan (VMP)
- Released July 2025
- Guideline, not a code or regulation



ASHRAE/ASHE 43 Fills Longstanding Compliance Gap

ASHRAE 170, Ventilation of Health Care Facilities

- Design standard – not intended to be an operational guideline
 - JC/CMS have treated it as such regardless!
- Historically used to guide operation of HVAC in healthcare
 - Required by CMS – 2008 edition (or version in place at time of design/construction)
- No insight on managing excursions from temperature, humidity, or relative pressure requirements
- No guidance on monitoring for excursions

What is a Ventilation Management Plan?

- Comprehensive management document
- Guidelines on inspection and maintenance activities
 - Based on manufacturer's requirements, infrastructure capabilities, and risk ranking
- Clarity on addressing unexpected ventilation excursions
 - Internal policies and procedures to address temperature, rH, or pressure excursions



Developing your Ventilation Management Plan

1. Identify Stakeholders

- Multi-disciplinary – should go beyond Facilities/Engineering
- Infection Prevention/Control
- Other key stakeholders
 - Surgical Services
 - Transplant
 - Oncology
- Consider creating a Ventilation Management Committee
 - Combine with water management committee?

Developing your Ventilation Management Plan

2. Assess Systems and Spaces

- What spaces require special temperature, humidity, relative pressure?
- Do you have an inventory?
- Is it reviewed regularly?
- Consider NFPA 99 systems ranking (Categories 1-4)

Key Decisions in Step 2

Must Identify:

- ☐ Critical vs. non-critical spaces
- ☐ Function/level of risk for each space with a requirement
- ☐ Specific temp/rH/pressure requirements
- ☐ Applicable version of code
- ☐ Frequency of monitoring

Developing your Ventilation Management Plan

3. Develop the Plan

- Define maintenance intervals (as needed)
 - Encourages the use of reliability-centered maintenance practices to optimize system performance and resource use (where allowed by code)
- Schedule for measuring/monitoring temperature/rH/pressure
- Outline excursion response plans
 - Planned and unplanned excursions
 - Time-based
 - Risk-based

Developing your Ventilation Management Plan

4. Establish Policies

- Based on response plans
- Educate staff



Essential Information for a Model VMP Program

Compliance Reference

- Year of Design (for every space)
- Use of Most Current Standard applicable to your newest area of the hospital for all areas
- Use of Most Current Standard

Monitoring

- Parameters to be monitored
- Frequency of monitoring
- Risk-Based Frequency

Excursion Management

- What response will occur with an excursion?
- Risk-based where some excursion for some limit of time result in increase monitoring
- When to close spaces

Maintenance

- Manufacturer recommendations
- Reliability-centered maintenance



Regulatory Implications

Joint Commission – Previous Standard

- EC.02.05.01 Risks Associated with Utility Systems
- EP 15: In critical care areas designed to control airborne contaminants (such as biological agents, gases, fumes, dust), the ventilation system provides appropriate pressure relationships, air-exchange rates, filtration efficiencies, temperature and humidity.
 - ORs, Protective Environment Rooms (positive); Airborne Infection Isolation Rooms (negative)
 - Form and function of assessment per hospital policy
- EP 16: In non-critical care areas, the ventilation system provides required pressure relationships, temperature, and humidity.
 - Note: Examples of non-critical care areas are general care nursing units; clean and soiled utility rooms in acute care areas; laboratories, pharmacies, diagnostic and treatment areas, food preparation areas, and other support departments.

Joint Commission – New Standard Jan. 1, 2026

- PE.04.01.01 Building Safety and Facility Management
- EP 3: The hospital has proper ventilation, lighting, and temperature control in all pharmaceutical, patient care, and food preparation areas



Use Case Scenarios for a VMP

Planned OR Temperature Excursions

- Expectation that OR temperature range is 68°F – 75°F and rH is <60%
- Humidity and pressure must stay within range/expected values
- Temperature excursions are allowed but **cannot** be blanket allowances
 - ASHRAE table specifies allowances to go outside required range
 - Must:
 - Have an established organizational policy
 - Be on a case-by-case basis
 - Be restored to normal ranges following the procedures (based on either surgeon, patient or procedure)
- Testing and Balancing reports requested/reviewed

Operating Room Temperature Excursions

- Ventilation Management Plan
- Work with OR leadership, IP/IC experts to determine parameters and processes for requesting an excursion
- Document, document, document!
 - Document process within the VMP
 - Each request for an excursion must be documented

Different Codes and Standards

- Many hospitals have built areas of their hospitals under different versions of ventilation codes
- Only required to meet the requirements of the code at the time of construction. But this can be confusing for some areas; you want to protect the patients regardless, and some work is required to document and assess risk
- One hospital had 6 different versions of the FGI/AIA/ASHRAE 170 guidelines applicable to their hospital. Decision included:
 - Important differences include All anteroom pressure differences, Endoscopy pressure, humidity requirements, and OR air exchanges
 - Client did not try to/could not achieve the increased air exchange rates
 - Some relative pressure requirements were taken from the newer version of the code for standardization/patient protection
 - Risk assess and document in VMP

Case Studies:
How Adopting ASHRAE 43 Can Strengthen Your
Infection Prevention Program

Case Study 1: Unplanned Relative Humidity Excursion


Background

- Relative humidity exceeded FGI guidelines during the day for 3 days in mid-summer
- Temporary measures were taken; however, non-compliance continued.
- Disagreement among leaders on the correct actions to take
 - Some leaders thought the supplies had to be disposed of (thousands of dollars)
 - No clear guidelines in ASHRAE 170

Outcome


- Issue resolved due to weather change but client wanted a plan implemented for future
 - EH&E designed a surveillance and risk assessment program
 - A clear policy and decision algorithm was developed to document how these issues would be addressed going forward

Critical Area Temperature, Relative Humidity (RH) or Pressurization Alert Algorithm



Case Study 1: How a VMP Would Have Improved Response

- Response is not delayed while a plan is developed in the “heat of the moment”
- VMP includes a planned excursion response that enables a more rapid, smooth response
- Correct actions would have been previously agreed to by all stakeholders and documented
- Eliminate disagreements among leaders



Why a VMP May Be Even More Needed in the Future

According to Climate Central, Columbia University research found climate change is increasing the number of extreme humid heat days. In most regions, humid heat extremes have already doubled in frequency since 1980.

Parts of New England have increased by 2.5 times.

<https://www.climatecentral.org/climate-matters/humid-heat-extremes-on-the-rise>

https://news.climate.columbia.edu/2020/05/08/fatal-heat-humidity-emerging/?shareadraft=baba77757_5e8c736da48a5

Case Study 2: Relative Pressure Monitoring Gap


Background

- Bacterial infections in one OR lead to physical environment assessment
- Laminar airflow design
- Prior assessment observed issues with downflow velocity
- Pressurization was found out of compliance/design specification from sub-sterile room

Outcome


- Change monitoring procedure to reflect adjacencies

Investigation



Case Study 2: How a VMP Would Have Improved Response

- Clarity on which areas get assessed for pressure
 - Though a pressure sensor is not required on all doors, it can be part of a periodic assessment of high-risk spaces
- Team knowledge is a key element of VMP including with clinical users





Wrap-up

Benefits from an Infection Prevention Perspective



Improved Reliability



Enhanced Infection Prevention



Standardized Practices



Excursion Management

From a Regulatory Vantage Point

- ASHRAE 43 is a guideline – compliance is not required, but there are strong benefits to adoption
 - Documentation of risk assessments/procedures for planned excursions
 - Creation of process for unplanned excursions
- Unknown future adoption by Authorities Having Jurisdiction
 - Still must maintain compliance with FGI/ASHRAE 170
 - Any deviation must be documented
 - Excursions or other design standards
- Make sure staff can speak to plans/procedures



Bryan Connors, M.S., CIH
Managing Principal Consultant,
Healthcare
bconnors@eheinc.com
[in/bryan-connors/](https://www.linkedin.com/in/bryan-connors/)

ASHRAE 43 Provides Clarity on Healthcare Ventilation Management





eheinc.com
800-825-5343

Thank You!

Biography: Scott Roberts, MD

Scott Roberts trained at the Albert Einstein College of Medicine in Bronx NY, completed his internal medicine training at the University of Michigan, Ann Arbor, and his infectious diseases training at Northwestern Memorial Hospital, Chicago IL. He started as an Assistant Professor in Infectious Diseases at the Yale School of Medicine in 2020, where he also has an administrative role as the Associate Medical Director, Infection Prevention, Yale New Haven Hospital.





Measles

Scott C Roberts, MD, MS

May 01, 2026

Assistant Professor, Infectious Diseases

Associate Medical Director, Infection Prevention

Yale School of Medicine | Yale New Haven Health

scott.c.roberts@yale.edu

Yale Medicine

Yale
New Haven
Health

Disclosures

Shionogi – advisory board, COVID-19 antivirals

Pfizer – advisory board, COVID-19 antivirals

Learning objectives

Learn the core concepts of preventing measles in healthcare

Recognize the methods for identifying and diagnosing measles infection

Understand the impact of measles and future strategies to prevent spread



Case

Yale Medicine

Yale
NewHaven
Health

Case

9 year old boy presents to the ED

- Fever (T max 104) x 6 days
- Day prior to the ED he developed a rash on his cheeks that spread to the neck and trunk
- Also with cough, rhinorrhea, decreased oral intake, and lethargy
- Denies sore throat, shortness of breath, diarrhea
- ROS: lethargy, decreased oral intake

Case

Exam:

Vitals: T 99.7, P 123, BP 97/67, R 18, O2 99% RA

Gen: no distress, conversant

HEENT: congestion and rhinorrhea present, mucous membranes dry

CV: regular rate and rhythm, no murmurs, rubs, or gallops

Pulmonary: clear to auscultation bilaterally, no wheezes, rales, or rhonchi

Extremities: no edema, morbilliform erythematous rash involving face, neck, trunk, and upper extremities





Next steps?

- Anything else you want to know?
 - Recent travel to Mexico two weeks ago
 - He is partially up to date on his childhood vaccines and has never received MMR
 - No direct exposure to anyone with measles
 - Everyone else in the family (including siblings) are well

Conduction an investigation

- 1) Prepare
- 2) Confirm the diagnosis**
- 3) Determine existence of outbreak
- 4) Identify (case definition) and count cases
- 5) Tabulate data, person, place, and time
- 6) Immediate control measures
- 7) Develop and test hypothesis
- 8) Systemic study of outbreak
- 9) Implement and evaluate control and prevention measures
- 10) Communicate

High impact pathogen

- 1) Identify**
- 2) Isolate
- 3) Inform

Fever and rash 2019- The viral exanthem



EBV after amoxicillin



Parvovirus B19



Varicella- chicken pox



Parvovirus B19

HHV-6 (roseola, sixth disease)

Enterovirus

Adenovirus

Antibiotic sensitivity reactions, allergies

What's old is new: Fever and rash 2025- expanding the differential dx



I am
back!!!!



Measles
(Morbillivirus)

Giant microbes

ED differential:

- Measles
- Kawasaki disease
- Parvo B19 (erythema infectiosum)
- Streptococcal pharyngitis
- Other viral exanthem (hand, foot, and mouth)

Measles Rash

- Typical presentation:
 - Starts on face, at hairline, or behind ears
 - Spreads downwards to neck, trunk, extremities
 - Maculopapular
 - Small raised or flat bumps
 - Spots may join together as the rash spreads
 - Not usually itchy
 - Koplik spots may be present on buccal mucosa



Measles rash



Koplik Spots

<https://www.nhs.uk/conditions/measles>

Measles symptoms typically include:


- ☐ High fever
- ☐ Runny nose
- ☐ Red, watery eyes
- ☐ Rash that breaks out 3-5 days after symptoms begin
- ☐ The 3 C's: cough, coryza, conjunctivitis

If high index of suspicion of measles, isolate and notify provider.



Red book 2018

C Disease course



Establish the diagnosis

- 1) Must be a susceptible patient (there has been disease in previously vaccinated older patients)
- 2) Compatible clinical syndrome - 3 C's, rash
- 3) Laboratory confirmation of disease

Serology?

- Commercial IgM not reliable
- IgG for immunity
- Seroconversion can be helpful

How to test? Approval for state lab testing

**Nasopharyngeal swab
is DPH test of choice**



Investigation

- Patient is discharged home with instructions to isolate
- What now?
 - For the patient?

 Measles PCR (CT State Lab) (BH GH LMH YH)

Status: **Final result** Next appt: **None**

Test Result Released: **Yes (seen)**

Specimen Information: Nasopharynx; Viral


2 [Result Notes](#)

[View Follow-Up Encounter](#)


Component	12/9/25 5:21 PM
Ref Range & Units	
Measles PCR	Detected !
Not Detected	

The virus

- Single stranded RNA paramyxoviridae family, Morbilliform genus
- **Only 1 serotype**, humans are the only host



JOURNAL OF VIROLOGY, Feb. 1969, p. 187-197




Measles virus spreads first to local lymphoid tissue and is then disseminated throughout the blood stream through infected lymphocytes, infecting cells in almost all organ systems

The incubation period for measles is 12.5 days on average (95% CI 11.8-13.2 days), with a range up to 23 days

Lancet 2017; 390: 2490-502


- Infects lymphoid tissue and lymphocytes
- Spreads via blood stream

Complications of measles



CDC

D Complications



Lancet 2017; 390: 2490-502

Yale SCHOOL OF MEDICINE

Yale
NewHaven
Health
Yale New Haven
Hospital

People at High Risk for Complications

People at high risk for severe illness and complications from measles include:

- Infants and children aged <5 years
- Adults aged >20 years
- Pregnant women
- People with compromised immune systems, such as from leukemia and HIV infection

Important in thinking about prevention in the outbreak setting

Subacute Sclerosing Panencephalitis (SSPE)

- Rare, but fatal progressive neurologic disease
 - Higher incidence in children who are infected with measles when <2 years old
- Onset on average 7 years after infection, but could present decades after
- Clinical symptoms
 - Initially mild, mental deterioration (memory loss, behavioral changes)
 - Progression to myoclonic seizures, motor disability, and eventually to a persistent vegetative state
 - Death typically occurs within 1–3 years of diagnosis

Measles Treatment

- There is no specific antiviral agent for measles treatment
- CDC recommends vitamin A supplementation for hospitalized children
 - Vitamin A dosing (once daily x2 days):
 - › Infants <6 months: 50,000 international units
 - › Infants 6 to 12 months: 100,000 international units
 - › Children $\geq$ 12 months: 200,000 international units
- Measles virus is susceptible to ribavirin in vitro but data on clinical use and efficacy are extremely limited
 - Ribavirin could be considered, in consultation with an infectious disease expert, for patients with severe measles complications or immunocompromised patients

Investigation

- Patient is discharged home with instructions to isolate
- What now?
 - For the patient?
 - For healthcare workers and other patients?

 Measles PCR (CT State Lab) (BH GH LMH YH)

Status: **Final result** Next appt: **None**

Test Result Released: **Yes (seen)**


Specimen Information: Nasopharynx; Viral

2 [Result Notes](#)

[View Follow-Up Encounter](#)

Component	12/9/25 5:21 PM
Ref Range & Units	
Measles PCR	Detected !
Not Detected	

Infectivity



Note: Average case-fatality rates and transmission numbers are shown. Estimates of case-fatality rates can vary. The preliminary estimates for the new coronavirus are shown in the pink region.

Source: NYTimes

Measles Transmission at a Domestic Terminal Gate in an International Airport — United States, January 2014

Jared S. Vega, JD¹, Miguel Escobedo, MD¹, Cynthia R. Schulte²,
Jennifer B. Rosen, MD³, Stephanie Schauer, PhD⁴, Rachel
Wiseman, MPH⁵, Susan A. Lippold, MD¹, Joanna J. Regan, MD¹
(Author affiliations at the end of text)

Patients 1 and 2 traveled on the same flight from the airport and were seated one row apart; both spent time at the departure gate before the flight. Patient 3, whose flight departed after the flight of patients 1 and 2, also reported spending time at this gate area during the time that patients 1 and 2 were present. Patient 4 passed through the same domestic gate around the time the other three patients were waiting to depart.

Required protection in the community

Table 1. Estimates of the critical percentage of susceptible persons that must be vaccinated to eradicate a given disease from a population

Disease	Critical percentage of susceptible persons that must be vaccinated to eradicate a disease (% of susceptible persons)
Measles	90-95
Pertussis	90-95
Fifth ^a	90-95
Chickenpox	85-90
Mumps	85-90
Rubella	82-87
Poliomyelitis	82-87
Diphtheria	82-87
Scarlet fever	82-87
Smallpox	70-80

Pockets of populations where the level is lower


Publisher: CDC; Journal: Emerging Infectious Diseases Article Type: Research;
Volume: 7; Issue: 6; Year: 2001; Article ID: 01-0607

MEASLES CASES – AS OF 19 APRIL 2026

2026 CASES
1784 CONFIRMED CASES

2025 CASES
2288 CONFIRMED + 4 PROBABLE CASES
AND 3 DEATHS

2025 - 2026 CASES
4072 CONFIRMED + 4 PROBABLE CASES and 3 DEATHS



STATE	CASES					DEATHS
	NEW	2025+2026	CONFIRMED 2026	CONFIRMED 2025	PROBABLE 2025	
SOUTH CAROLINA	1	1001	668	333		
UTAH	6	603	406	197		
TEXAS	4	985	180	805		2
FLORIDA	1	153	145	8		
ARIZONA	7	300	79	221		
CALIFORNIA	4	66	40	26		
WASHINGTON	4	49	37	12		
NORTH DAKOTA	1	69	33	36		
NORTH CAROLINA	0	24	22	2		
OREGON	6	21	20	1		1
VIRGINIA	1	23	17	6		
NEW MEXICO	0	116	16	100		
MINNESOTA	1	42	16	26		
COLORADO	1	52	16	36		
PENNSYLVANIA	0	28	12	16		
OHIO	0	56	11	45		
IDAHO	0	23	9	14		
SOUTH DAKOTA	0	24	8	16		
MICHIGAN	0	38	8	30		
MAINE	0	5	5	0		
MONTANA	0	41	5	36		
NEW YORK	0	32	4	28		
NEW YORK CITY	0	24	4	20		
KENTUCKY	0	18	4	14	1	
ILLINOIS	0	18	4	14		
NEBRASKA	0	6	3	3		
GEORGIA	0	12	2	10		
MASSACHUSETTS	0	2	2	0		
WISCONSIN	0	38	2	36		
ALASKA	0	5	1	4		
MARYLAND	1	4	1	3		
MISSOURI	0	8	1	7		
OKLAHOMA	0	18	1	17	3	
RHODE ISLAND	1	2	1	1		
VERMONT	0	3	1	2		
ALABAMA	0	1	0	1		
ARKANSAS	0	8	0	8		
CONNECTICUT	0	1	0	1		
HAWAII	0	2	0	2		
INDIANA	0	11	0	11		
IOWA	0	9	0	9		
KANSAS	0	91	0	91		
LOUISIANA	0	3	0	3		
NEVADA	0	2	0	2		
NEW JERSEY	0	12	0	12		
TENNESSEE	0	8	0	8		
WYOMING	0	15	0	15		
TOTAL	38	4072	1784	2288	4	3

OUTBREAKS

- SMALL OUTBREAK (3-9)
- MEDIUM OUTBREAK (10 - 49)
- LARGE OUTBREAK (50 OR MORE)

An outbreak of measles is defined as three or more laboratory-confirmed cases that are temporally related and epidemiologically or virologically linked.

2026

Total: 1784

AGES

21% - Under 5
51.3% - 5-19 years of age
27.2% - 20+ years of age
.5%- Unknown

92% of all cases were unvaccinated or had unknown vaccination status, 4% had 1 MMR dose, and 4% had 2 MMR doses.

6% of all cases required hospitalization

2025

Total: 2288

AGES


26% - Under 5
44% - 5-19 years of age
30% - 20+ years of age
1% - Unknown

93% of all cases were unvaccinated or had unknown vaccination status, 3% had 1 MMR dose, and 4% had 2 MMR doses.

11% of all cases required hospitalization

International importations, 2001–2024*

During 2001–2024, 64% of importations occurred among US residents



*2024 data shown here as of 3/28/2024. Data summarizing measles surveillance during 01/01/2020–3/28/2024 can be found here:

<https://www.cdc.gov/mmwr/volumes/73/wr/mm7314a1.htm>

Droplet versus aerosol


The difference between droplet and airborne transmission

Droplet transmission

Coughs and sneezes can spread droplets of saliva and mucus

Airborne transmission

Tiny particles, possibly produced by talking, are suspended in the air for longer and travel further



Source: WHO

BBC



Measles in healthcare settings

- 1) **Ensure all HCW have presumptive immunity to measles**
- 2) Minimize potential exposures
- 3) Adhere to standard AND airborne precautions
- 4) Manage measles exposures
- 5) Considerations for an outbreak
- 6) Train and educate HCP
- 7) Report within hospital and to public health authorities

Who is immune?

Evidence of Immunity

Acceptable presumptive evidence of immunity against measles includes at least **one** of the following:

- written documentation of adequate vaccination:
 - one or more doses of a measles-containing vaccine administered on or after the first birthday for preschool-age children and adults not at high risk
 - two doses of measles-containing vaccine for school-age children and adults at high risk, including college students, healthcare personnel, and international travelers
- laboratory evidence of immunity
- laboratory confirmation of measles
- birth before 1957

MMR Vaccine Contraindications

- Severe immunocompromising conditions (e.g., hematologic malignancy, receipt of chemotherapy, long-term immunosuppressive therapy)
 - HIV if CD4 % < 15% or absolute CD4 < 200
- Family history suggestive of a congenital immunocompromising condition, unless assessed to be immunocompetent by a clinician or laboratory testing
- History of severe allergic reaction to MMR or to an MMR vaccine component
- Pregnancy

<https://www.cdc.gov/measles/hcp/vaccine-considerations/index.html>

MMR Vaccine Adverse Events

- MMR vaccine is generally very well tolerated
- Common side effects include:
 - Fever (<15%)
 - Brief rash (5%)
 - Lymphadenopathy (5% of children, 20% of adults)
- Rare serious adverse events include:
 - Anaphylaxis (2–14 events per million doses)
 - Febrile seizures (1 event per 3–4,000 doses)
 - Low platelet count (1 event per 40,000 doses; may be higher risk if known ITP)

MMR Can Cause a Self-limited Rash

- MMR can cause a short-lived febrile rash syndrome that is not contagious to others
- Differentiating measles from an MMR reaction in the setting of an outbreak can be challenging, especially if MMR was given to prevent measles after an exposure




MMR reaction (not contagious)

Non-medical vaccine exemptions are increasing


National and State Level 2-dose MMR Coverage

	2019-2020	2020-2021	2021-2022	2022-2023
MMR (2 doses)	95.2	93.9	93.0	93.1

MMR Vaccination among Kindergartners 2022 - 2023



Change in kindergarten measles vaccination rates




Prepandemic is the average of 2017-18, 2018-19 and 2019-20 data, though not all years were available for all states. Alabama, Florida, Georgia, Iowa, Mississippi, New Hampshire, New Jersey and Delaware (in 2024) report the rate of students who have completed all required vaccines, not just the measles series. Source: Centers for Disease Control and Prevention

Measles in healthcare settings

- 1) Ensure all HCW have presumptive immunity to measles
- 2) Minimize potential exposures**
- 3) Adhere to standard AND airborne precautions
- 4) Manage measles exposures
- 5) Considerations for an outbreak
- 6) Train and educate HCP
- 7) Report within hospital and to public health authorities

Minimize exposures

- Notify healthcare facility in advance
- PUI should don mask
- Separate from other patients as soon as possible



Measles in healthcare settings

- 1) Ensure all HCW have presumptive immunity to measles
- 2) Minimize potential exposures
- 3) **Adhere to standard AND airborne precautions**
- 4) Manage measles exposures
- 5) Considerations for an outbreak
- 6) Train and educate HCP
- 7) Report within hospital and to public health authorities

Precautions

- AIIR – exhaust to outside or HEPA

ACH § 11	Time (mins.) required for removal 99% efficiency	Time (mins.) required for removal 99.9% efficiency
2	138	207
4	69	104
6+	46	69
8	35	52
10+	28	41
12+	23	35
15+	18	28
20	14	21
50	6	8

The number of air changes per hour and time and efficiency.



Measles in healthcare settings

- 1) Ensure all HCW have presumptive immunity to measles
- 2) Minimize potential exposures
- 3) Adhere to standard AND airborne precautions
- 4) Manage measles exposures**
- 5) Considerations for an outbreak
- 6) Train and educate HCP
- 7) Report within hospital and to public health authorities

Measles exposures

HCW exposed

- Asymptomatic WITH immunity: status quo
- Asymptomatic WITHOUT immunity: PEP, quarantine 5 – 21 days after exposure

regardless of PEP

- Infected with measles: isolate x 4 days after rash appears

Patients/family exposed

- airborne day 5 – 21 after exposure
- PEP
- Immunoglobulin may extend incubation period to 28 days

< 6 month old (non-immune due to age)

Time since initial exposure:

≤ 6 days:	> 6 days:
Give intramuscular immunoglobulin (IMIG) (dosing)	PEP not indicated (too late)
Home quarantine for 28 days after last exposure	Home quarantine for 21 days after last exposure

6-11 months old (non-immune due to age)

Time since initial exposure:

≤ 72 hours (3 days):	4-6 days:	> 6 days:
Give MMR vaccine (preferred over IG)	Give intramuscular immunoglobulin (IMIG) (dosing)	PEP not indicated (too late)
No quarantine needed if MMR PEP given	Home quarantine for 28 days after last exposure	Home quarantine for 21 days last after exposure

≥12 months and non-immune

Time since initial exposure:


≤ 72 hours (3 days):	≥ 4 days:
Give MMR vaccine	PEP not indicated (too late)
No quarantine needed if MMR PEP given	Home quarantine for 21 days after last exposure, then give MMR vaccine to protect from future exposures

Measles in healthcare settings

- 1) Ensure all HCW have presumptive immunity to measles
- 2) Minimize potential exposures
- 3) Adhere to standard AND airborne precautions
- 4) Manage measles exposures
- 5) Considerations for an outbreak**
- 6) Train and educate HCP
- 7) Report within hospital and to public health authorities


Tempo of illness from exposure to diagnosis

FIGURE. Time from hospital emergency department (ED) exposure and rash onset until laboratory confirmation of measles among six patients — Pennsylvania, March–April 2009



Measles in healthcare settings

- 1) Ensure all HCW have presumptive immunity to measles
- 2) Minimize potential exposures
- 3) Adhere to standard AND airborne precautions
- 4) Manage measles exposures
- 5) Considerations for an outbreak
- 6) Train and educate HCP**
- 7) Report within hospital and to public health authorities



Questions?

Common FAQs

If my patient is a 7 mo old and traveling within the United States should they get a MMR vaccine early?

- No, the only current indications for early vaccination is international travel or as recommended by a state DPH during an outbreak.
- If traveling to a domestic area where there is active transmission, early vaccination can be considered.

Vaccine <1 yr does not count toward the vaccine series

Common FAQs

I was born in 1965. I know I received a measles vaccine but I do not have written records of vaccination. Should I get an MMR vaccine?

People who previously received a dose of measles vaccine in 1963–1967 and are unsure which type of vaccine it was, or are sure it was inactivated measles vaccine, should be revaccinated with either one (if low-risk) or two (if high-risk) doses of MMR vaccine. If the vaccine given was the live virus vaccine, the dose is considered valid and does not need to be repeated.

Common FAQs

Are there situations when more than 2 doses of MMR are recommended?

There are two circumstances when a third dose of MMR is recommended. ACIP recommends that women of childbearing age who have received 2 doses of rubella-containing vaccine and have rubella serum IgG levels that are not clearly positive should receive 1 additional dose of MMR vaccine (maximum of 3 doses). Further testing for serologic evidence of rubella immunity is not recommended. MMR should not be administered to a pregnant woman.

In 2018, ACIP published guidance for MMR vaccination of people at increased risk for acquiring mumps during an outbreak. People previously vaccinated with 2 doses of a mumps virus-containing vaccine who are identified by public health authorities as being part of a group or population at increased risk for acquiring mumps because of an outbreak should receive a third dose of a mumps virus-containing vaccine (MMR or MMRV) to improve protection against mumps disease and related complications.

Common FAQs

A college student doesn't have vaccine records, but their titer shows they are not immune to a combination of measles, rubella, and/or mumps. What vaccine should the student receive?

Single antigen vaccine is no longer available in the U.S.; the student should get the combined MMR vaccine. If a college student or other person at increased risk of exposure cannot produce written documentation of either immunization or disease, and titers are negative, they should receive two doses of MMR.

Common FAQs

A patient born in 1970 has a history of measles disease and is also immunosuppressed due to multiple myeloma. The patient wants to travel to Africa, but is concerned about the measles exposure risk. Should the patient receive the MMR vaccine?

A history of having had measles is not sufficient evidence of measles immunity. A positive serologic test for measles-specific IgG will confirm that the person is immune and is not at risk of infection regardless of the multiple myeloma. Multiple myeloma is a hematologic cancer and is considered immunosuppressive so MMR vaccine is contraindicated in this person.

Common FAQs

I have a 45-year-old patient who is traveling to Haiti for a mission trip. She doesn't recall ever getting an MMR booster (she didn't go to college and never worked in health care). She was rubella immune when pregnant 20 years ago. Her measles titer is negative. Would you recommend an MMR booster?

ACIP recommends 2 doses of MMR given at least 4 weeks apart for any adult born in 1957 or later who plans to travel internationally. There is no harm in giving MMR vaccine to a person who may already be immune to one or more of the vaccine viruses.

Common FAQs

Is there any harm in giving an extra dose of MMR to a child of age seven years whose record is lost and the mother is not sure about the last dose of MMR?

In general, although it is not ideal, receiving extra doses of vaccine poses no medical problem.

Vaccination providers frequently encounter people who do not have adequate documentation of vaccinations. Providers should only accept written, dated records as evidence of vaccination. With the exception of influenza vaccine and pneumococcal polysaccharide vaccine, self-reported doses of vaccine without written documentation should not be accepted. An attempt to locate missing records should be made whenever possible by contacting previous healthcare providers, reviewing state or local immunization information systems, and searching for a personally held record.

If records cannot be located or will definitely not be available anywhere because of the patient's circumstances, children without adequate documentation should be considered susceptible and should receive age-appropriate vaccination. Serologic testing for immunity is an alternative to vaccination for certain antigens (e.g., measles, rubella, hepatitis A, diphtheria, and tetanus).

Yale SCHOOL OF MEDICINE

Common FAQs

Is there any evidence that MMR or thimerosal causes autism?

No. This issue has been studied extensively, including a thorough review by the independent Institute of Medicine (IOM). The IOM issued a report in 2004 that concluded there is no evidence supporting an association between MMR vaccine or thimerosal-containing vaccines and the development of autism. For more information about MMR vaccine safety, see the measles chapter of CDC's Epidemiology and Prevention of Vaccine-Preventable Diseases (known as the "Pink Book"), at www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-13-measles.html#cdc_report_pub_study_section_10-vaccine-safety. For more information on thimerosal and vaccines in general, visit www.cdc.gov/vaccine-safety/about/thimerosal.html.

Questions?

Thank you!

Biography: Jason Contrady, MBA, PMP, LSSGB, NREMT

Jason is a Senior Project Manager at Dartmouth Health. He has over a decade of experience leading diverse teams, implementing large-scale projects, and driving quality improvements across different industries. Currently, he guides system-wide strategic integration initiatives to improve quality, safety, and patient care. Much of Jason's 15-year career was spent in supply chain planning, operations, and software in wholesale distribution and retail while spearheading emergency response and federal grants as a public servant. An advocate for continuous learning and innovation, Jason is passionate about equipping others with practical tools to succeed. He thrives on exploring complex systems, distilling technical concepts, and transforming ideas into reality. Jason holds a Project Management Professional (PMP) certification, an MBA from Colby- Sawyer College, a BS in Finance and Supply Chain from Northeastern University and is Lean Six Sigma Green Belt certified through the Dartmouth Health Value Institute Learning Center. He is an active National Registry EMT, Firefighter I, Deputy Fire Chief, and Emergency Management Director in Surry, New Hampshire.



Project Management Fundamentals For Infection Prevention

From Policy to Practice:

Co-Creating an Infection Prevention Rollout Plan

as

signature

gr ou rifi

n

m p_ ed

ad _u


en

d sor

© 2026 Jason Contrady

What Is a Project?

A temporary endeavour undertaken to create a unique product, service, or result.¹



A project has a defined goal, a beginning, and an end.

There Is a Profession for Managing Projects

assignment Project Management

Managing a temporary initiative to create a unique product or service.

Focus: "One effort"
Execution, scope, budget.

PMP®, CAPM®

account_tree Program Management

Managing a group of related projects to obtain strategic benefits.

Focus: "Related efforts"
Strategic alignment.

PgMP®

dashboard Portfolio Management


Centralized management to achieve high-level strategic objectives.

Focus: "Right work"
Value & resource allocation.

PfMP®

Project Management skills aid effectiveness, even without professional certification.

How This Looks in Healthcare



What We'll Do Today

assignment

Plan

Build a basic rollout plan.

sync_alt

Experience



Experience change.

visibility

Observe

See why change management matters.

A Group Becomes a Team Through Shared Work



Projects turn groups into teams by organizing people around a common outcome.

Scenario: MGM Health

MGM Health is implementing a new single-use needles policy across inpatient and ambulatory clinical spaces.

location_city

The Setting

- 300-Bed Community Hospital
- 1 Ambulatory Surgery Center (ASC)
- 4 Outpatient Clinics

gavel

The Policy

Mandatory Single-Use
Needles in all clinical
spaces.

timer

Your Task

Draft your Plan.

*"Assume a smooth sail. What
does a perfect rollout look like?"*

Build Your Plan

groups

Work with your
table

description

Use the
templates

psychology

Aim for practical
decisions

done_all

You do not need
perfect answers

Tools and Templates

assignment
Charter (mini)

group_assignment
Stakeholder Plan

grid_view
RAM
Responsibility
Assignment Matrix

campaign
Communication Plan

fact_check
Milestone Timeline

Build a practical rollout plan for MGM Health.

Tool 1: Charter (mini)

Objective

[Define the primary goal of the rollout]

In Scope

- *Included departments*
- *Specific deliverables*
- *Budget items*

Out of Scope

- *Future phases*
- *Excluded facilities*
- *Non-clinical areas*

Tool 2: Stakeholders

group_added

Who is affected?

BC

mu

psi

Nurses &
Physicians

Supply
Chain

m

ed

ha

pls

Educators &
Leadership

Ambulatory
Staff

Likely reaction



Resistance



Neutral



Champion

What might they gain or lose?

GAINS

Improved Safety, Standardized Workflow, Better Patient Outcomes


LOSSES / RISKS

Time (Training), Muscle Memory, Initial Efficiency Drop

Deep Dive: The Stakeholder Map

Strategies for stakeholder groups

group_ad
d



Action Item: Draft Mitigation Strategies for each group. How do you turn a challenge into a partnership?

Tool 3: Responsibility Assignment Matrix (RAM/RACI)

grid_view

Activity	Project Lead	Clinical Educator	Supply Manager	Executive Sponsor
Education	A	R		
Supply readiness	A		R	
Policy communication	R			A
Audit follow-up	A	C		

R Responsible A Accountable C Consulted I Informed

There can be only ONE 'A' (Accountable) per activity row.

Tool 4: Communication Plan


campaign

Audience	Message	Channel	Concern to Address
Frontline Clinicians	Safety & Workflow	groups Daily Huddle	<i>Impact on patient time and muscle memory</i>
Department Leads	Resource Support	forum Leader Briefing	<i>Budget and staffing for training phases</i>
All Employees	Why it Matters	mail Email/Intranet	<i>Consistency across the health system</i>

Ensure messages are consistent, frequent, and address specific "losses" identified earlier.

Tool 5: Milestone Timeline

fact_chec
k



At Your Table: How to Work the Exercise

Assign quick roles and build a practical starter plan.

Assign 4 Roles

Scribe — captures the group's decisions on the worksheet

Timekeeper — keeps the table moving through each step

Spokesperson — guides discussion and speaks for the Team

Sponsor — ensures the Team delivers the objective

Your Goal by the End

- A one-sentence implementation objective
- 2–3 key stakeholders and likely concerns
- Basic role ownership
- 2–3 communication actions
- A short milestone sequence

Keep it practical and high level. Build a usable outline, not a perfect plan.

Objective: MGM Health Policy

timer 10 min

Implement a new single-use needles policy across inpatient and ambulatory clinical spaces.

assignment
nt

Charter (mini)

group_assignment
d

Stakeholder Plan

grid_view
RAM

Responsibility
Assignment Matrix

campaign

Communication Plan

fact_check
k

Milestone Timeline

Setting

300-Bed Community Hospital | 1 Ambulatory Surgery Center (ASC) | 4 Outpatient Clinics

Build a practical rollout plan for MGM Health.

New Direction

timer **5 min**

SW

Stop. Put your pens down.

ap
per
h
so
ori
n
pri
z
ad
ori
d
ty
alt
rig

Be more collaborative

Exchange your draft with a neighboring table

Representative

Send one liaison to discuss the transition

Authority

A sponsor from another team must sign-off on your documents

Pause: What Just Happened?

history

What changed?

groups

**How did your table
react?**

psychology

**What helped you
adapt?**


The Tuckman Curve in Real-Time

Forming: Where did we start?
(Optimism)


Storming: Where are you now?
(Frustration, Anxiety)

Norming: Where did we come from?
(Collaboration, Problem Solving)

Performing: The destination.
(Mastery, Resilience)



The Change Arc



Why Change Management Matters

as

Technical Rollout Plan

cal

en

Defined Tasks & Roles

da

Phased Timeline

set

tin

System Integration

as

vol

Adoption

for

te

Transparent Communication

ps

in

Trust & Psychological Safety

ya

ho

Support & Behavioral Change


log

in

Implementation succeeds when people adopt the change, not just when tasks are completed.

You Don't Need to be the PM to Drive Change

Every team member is a Change Agent.



Project Checklist

Charter (mini)

- Defines objective, scope, and success measures.
- Answers: What are we trying to accomplish?

RAM (RACI Matrix)

- Clarifies who is responsible and accountable.
- Defines ownership for key implementation tasks.

Milestone Timeline

- Outlines sequence of key checkpoints.
- Tracks readiness items and go-live actions.

Stakeholder Plan

- Maps groups, interests, and influence levels.
- Identifies likely support or resistance.

Communication Plan

- Targets messages, senders, and channels.
- Ensures audiences hear what they need to hear.

Change Management

- Accelerator through change uncertainty.
- Builds support loops for behavioral adoption.

Key Takeaways

Expect the Dip

The "Storming" phase is inevitable. Prepare for it.

Tools are Vehicles

Charts and matrices are useless without people.

Manage the Feeling

Your primary role is to guide your team from frustration to collaboration.

Change is not a step in the project. It is the project.

~~for~~
u

Q&A Discussion

Questions, reflections, and practical applications.

mailjason.conrady@pm.me

Thank You!

Biography: Lisa Giannakopoulos, RN, BSN

Lisa is a registered nurse with over 20 years of experience, with 3 of those years focused on Infection Prevention. She has led multiple quality improvement initiatives and has received 3 honorable achievement awards for enhancing patient safety at UCONN. She currently serves as the co-chair of the Water Management Committee at UCONN.





LEGIONELLA... The Silent Killer

Lisa Giannakopoulos, BSN, RN
UConn Health

*Figure 1. ([What is legionella],
n.d.)*

No disclosures



OBJECTIVES

- Review the history of legionella
- Discuss characteristics, transmission, treatment and prevention strategies
- Identify industry standards and regulations of Water Management Programs.
- Review case reporting, investigation, and controls measures
- Discuss the role of the Infection Preventionist in water management & legionella prevention
- Review the history of legionella in the United States and CT
- Examine the seasonal pattern of legionella
- Discuss the global burden and recent outbreaks



Figure 1. [Legionnaires' disease], (2021)

A word cloud centered around the word "legionella". The word "legionella" is the largest and most prominent, rendered in a dark blue, sans-serif font. Surrounding it are numerous other words in various sizes and shades of blue and teal. The words are arranged in a way that they appear to be floating around the central term. In the background, a hand is visible, holding a small white pill between the thumb and index finger. The overall composition suggests a medical or scientific theme related to the disease.

medicine
lung
patient
micro
care
analysis
serology
bacteria
test
assessment
syringe
pharmacy
pneumonia
legionnaires
microbiology
therapy
fever
disease
infection
research
malady
examine
tablets
diseased
medical
organism
biology
drug
exam
hematology
pharmaceutical
hospital
immunology
treats
laboratory
researcher
analyzing
capsule
ill
healthy
food
remedy
physician
diarrhea
illness
blood
doctor
epidemic
biological
pharmacist
sick
science
infectious
pills
lab
scientific
cdc
medication
sickness
virus
antibiotic
experiment
hygiene
flu
legionellosis
health

Figure 1 ([Legionella disease], n.d.)



The Bellevue-Stratford Hotel



1976 Legionnaires' disease outbreak



Figure 1 (Leonard, 2025)



Figure 2 (Wolfman-Arent, 2021)

-when cold air kills



Figure 3(Hingston,2016)



Within days of returning home, some of the veterans developed pneumonia and fatal respiratory infections.




Figure 1(The Lost Hotels, 2026)


Casualties



Figure 1 (Altman 2001)



Figure 2 (The Philadelphia Legionnaires' Outbreak, 2023)



The pneumonia-like symptoms were nearly the same in every case—muscle aches, headaches, severe coughs, diarrhea, chest pains and fevers as high as 107 degrees.


CASE 64
8/3/76

...they deemed
...apparently few of the victims
...exhibited gastrointestinal symptoms. ... Campen ...

**Same rooms,
same meals
and a question**

...Street, were not registered to go to
the convention. But, Hamberg re
counted yesterday, "we heard about
... and decided to drop ..."

...Nedmann



Investigative Team

- Epidemiologists
- State health workers
- Laboratories
- Medical staff in hospitals
- Investigators



Investigators Daily Meeting, Philadelphia, 1976

Figure 1 (Geothermal, 2020)




Figure 2 (Deher, 2015)



Figure 3 (Leonard, 2025)




Figure 1 (LaGarde,1996)





Figure 2 ([Graph at the Legionnaire's Disease Symposium], n.d)

Data Collection



David J Sencer CDC Museum: Legionnaires Exhibit



Figure 1 (Norman, 2025)

San Francisco Chronicle
The Largest Daily Circulation in Northern California

112th Year No. 173 ★★★ WEDNESDAY, AUGUST 4, 1976 777-1111 20 CENTS

Fear Among the Legionnaires

Williamsport, Pa. — Richard W. Snyder has been locking his forehead all day.

His best friend, William J. Hartman, 65, was in critical condition at Williamsport Hospital with the mysterious illness that has stricken American Legion members all over Pennsylvania.


Another friend, Charles Bennett, 40, was last Monday night when Snyder called him. Bennett entered the hospital yesterday afternoon, with the same fever and headache that has marked the illness in other legionnaires who

Rock Page Pix 2

Legion Mystery

Disease Toll Rising—Doctors Still Baffled

Figure 2 (O'Rourke, 2016)



The Aug. 16, 1976, cover of TIME TIME

Figure 3 (Disease Detectives Tracing the Philly Killer, 1976)



MEDIA FRENZY!



THE CLOSURE OF GROUND ZERO



The Bellevue-Stratford Hotel

Theories & Speculation




Figure 1 ([Legionnaires Disease-The Great Hoax, 2020])




Figure 2 (Hicklin, 2012)


A D E A D
 Some say it was radiation, some said: acid on the microphone
 A D E
 And some say it was a combination of things that turned their heart
 D E
 But whatever it was, it drove them to their knees
 E7 |: A . . . D . . . E . . . | :|
 Oh, that Legionnaire's disease

I wish I had a dollar for everyone that died within that year
 Got 'em grabbed by the collar, and plenty a maiden shed a tear
 Now beneath my heart, it sure put on a squeeze,
 Oh, that Legionnaire's disease
 It was Legionnaire's disease

Granddad fought in a revolutionary war, father in the War of 1812
 Uncle fought down in Vietnam and then he fought a war all by himself
 But whatever it was, it hit him like a tree
 Oh, that Legionnaire's disease
 It was Legionnaire's disease
 It was Legionnaire's disease
 It was Legionnaire's disease

Figure 1 (Dylan, 1978)

Bing Videos



Bob Dylan

Figure 2 (Davison, M., Fishel, P, 2023)


A Race Against Time



Figure 1
(Rossiter, 1976)



Figure 2 ([The baffling birth of Legionnaires' disease. Chronicle Covers], 1976.)



AIDING THE INVESTIGATION into toxins are Dr. F. William Sunderman Sr. (left) of Hahnemann Medical College and his son, Dr. F. William Sunderman Jr., of the University of Connecticut Medical School.

Figure 1(Wolfman-Arent, 2021)



Figure 2 (LaGarde, 1996)

Above-Normal Nickel Found in Legionnaires

Farmington, Conn. — (AP) — Scientists today found higher than normal nickel levels in tissue from victims of the mysterious legionnaires' disease.

They cautioned against premature conclusions in that high levels of nickel also were found in tissue from other humans.

The researchers are looking into the possibility that the Legion illness was caused by poisoning from nickel carbonyl.

After an American Legion convention July 21-24 in Philadelphia, 27 persons died and 128 others became ill, and their symptoms were similar to those of nickel carbonyl poisoning.

Dr. F. William Sunderman, who heads the University of Connecticut research team, said today nickel carbonyl is "one of the most toxic gases known." But he said he didn't know where it would have come from at the

Sunderman said he has asked for more tissue samples and added it would take several days to reach a conclusion. He said the tissue from the victims and the normal tissue were sent in the same container to Connecticut, raising the possibility of contamination.

When the tests are done, results will be sent from the UConn Health Center to the Center for Disease Control in Atlanta, Ga.

Doctors at the health center examined tissues from the lungs, brains and other organs of the victims. The symptoms of the 155 persons stricken with the illness "are very, very close to the classic description of nickel carbonyl poisoning," Sunderman said.

Allegheny County Coroner Cyril Wecht said yesterday in Pittsburgh that concentrations of crystals found in the kidneys of two victims indicate

Figure 3 (Wolfman-Arent, 2021)



Figure 4 (LaGarde, 1996)

17 Metals Dropped In Tests for Cause Of Legion Disease

By LAWRENCE K. ALTMAN

Special to The New York Times

HARRISBURG, Pa., Aug. 12

—The Center for Disease Control in Atlanta said today that 17 metals had been excluded as possible causes of the mysterious legionnaires' disease that has killed 27 persons in Pennsylvania.

Figure 5 (Altman 1996)

CDC Microbiologist Joseph McDade

"It's like looking for a contact lens on a basketball court with your eyes four inches above the ground,"

-New York Times interview with John McDade




Figure 1 (Center for Disease Control and Prevention, n.d.)



Figure 2 (Bouscher, 2023)




Figure 3 (Klein, 2006)



THE TURNING POINT: Christmas







Figure 1 ([Christmas tree 1978], 1978)

Figure 2 (Gordan, 2016)

The discovery: January 18, 1977






Figure 1 (Bouscher, 2023)

“As we broke the code and found out that they were falling into this particular pattern, I can still remember the hair raising up on the back of my neck.”

FORMER CDC MICROBIOLOGIST JOSEPH MCDADE

Figure 3 (LaGarde, 1996)




Figure 2 (LaGarde, 1996)

Feeley Gorman Agar




Figure 1 (Bouscher, 2023)

HOW WAS LEGIONELLA MISSED?







Figure 1 (LaGarde, 1996)



Figure 3 (LaGarde, 1996)



Figure 2 ([Erythromycin], n.d)



Figure 1 (Washington Post, 2019)



Figure 2 ([Pontiac Michigan], n.d)




Figure 3 ([Clue],
n.d.)

**ST. ELIZABETHS
MENTAL HOSPITAL
1965
&
PONTIAC FEVER
MICHIGAN 1968**

Legionella linked to cooling tower

The legionella bacterium was found to be breeding in the cooling tower of the hotel's air-conditioning system.




Figure 1 ([How cooling towers work], n.d.)




Figure 2 (Arsenault, 2017)



Burlington VT Hospital Outbreak 1977

Bloomington Indiana Outbreak 1978

- Campus of Indian University: 36,000 students centered around Indiana memorial union that houses students & clubs & hotel for visitors
- March 1978-Aug 1978
- 39 cases of legionella
- 3 deaths
- CDC investigated water tower and found legionella



Figure 1 ([Campus of Indiana University Memorial Union] , n.d.)

Memphis TN Hospital Outbreak 1978

- Baptist Hospital
- 44 cases, 0 deaths
- 2 samples water from air conditioning cooling tower were positive legionella



Figure 1 ([Baptist Memorial Hospital Memphis TN]
n.d.)



Oxford outbreak 1979

- Churchill hospital in Oxford
- Kidney transplant unit
- 2 cases of legionella, 6 months apart staying in the same room
- Legionella found in the shower head, from the facet head and the side arms of the shower head.

Figure 1 ([Oxford Churchill Hospital] n.d.)

Legionella species are Gram-negative bacilli.



Figure 1 ([Legionella on petri dish] , 2013)



Figure 2 ([Lake].n.d)




Figure 3 ([Legionella class] n.d)

Legionnaires disease (legionellosis)

a lung infection caused by the
bacterium **Legionella**




Figure 1[(Legionella lung infection] n.d.)

The NEW ENGLAND
JOURNAL of MEDICINE

CURRENT ISSUE ▾ SPECIALTIES ▾ TOPICS ▾

ORIGINAL ARTICLE | BRIEF REPORT

[f](#) [X](#) [in](#) [✉](#) [🦋](#)

A Cluster of Legionella Sternal-Wound Infections Due to Postoperative Topical Exposure to Contaminated Tap Water

Authors: Philip W. Lowry, M.D., Rosalind J. Blankenship, R.N., Wilma Gridley, R.N., Nancy J. Troup, and Lucy S. Tompkins, M.D., Ph.D. [Author Info & Affiliations](#)

Published January 10, 1991 | N Engl J Med 1991;324:109-113 | DOI: 10.1056/NEJM199101103240207

VOL. 324 NO. 2



Figures 2 & 3~ (Lowry et al, 1991)

Symptoms




Figure 1 ([Coughing].n.d.)

- ▶ Cough
- ▶ Shortness of breath
- ▶ Muscle aches
- ▶ Headache
- ▶ Fever

Risk Factors




Figure 2 ([Sick elderly], n.d.)

- ▶ Elderly (50 years and older)
- ▶ Smokers (current or former)
- ▶ Specific health issues/conditions:
 - ▶ Cancer
 - ▶ Chronic lung disease
 - ▶ Diabetes
 - ▶ Kidney & liver failure
 - ▶ Weak immune system

Modes of transmission

- Breathing in mist & water containing *Legionella*
- Swallowing water into the lungs, and aspiration of drinking water/ice chips containing *Legionella*




Figure 1 (CDC, 2025)




Figure 2 (CDC, 2025.)




Figure 3 (Legionnaires' Disease: What You Need to know, 2018)




Figure 4 (CDC, 2025.)

Sources of infection




Figure 1 (CDC, 2024.)

Respiratory
equipment

Car washes

Misting
devices

Street
cleaning
machines

Soil

Showerheads
and sink
faucets

Hot tubs

Decorative
fountains and
water features

Plumbing
systems

Contaminated
water or ice

Cooling
towers

Hot water
heaters

Humidifiers

Hospital
dishwashers

Diagnosing



Figure 1 ([Legionnaires' disease Xray], n.d.)

This frontal chest radiograph shows acute bilateral pneumonia (legionnaires' disease caused by *Legionella pneumophila*)



Figure 2 ([Legionella urine test], n.d.)



Figure 4 ([Legionella blood test], n.d)




Figure 3 [Legionella] culture test], n.d.)



Figure 5 ([Legionella PCR], n.d)

Is Legionnaires' disease contagious?



Legionnaires' disease
is NOT contagious.

NO!



Unlike many types of
pneumonia,
Legionnaires' disease
is NOT transmitted
directly from person to
person.

Patients with confirmed or suspected Legionella infection do not require isolation or contact precautions

Treatment & Prognosis

- Antibiotics: Azithromycin, Clarithromycin, or Levofloxacin.
- For individuals who contract the disease in health care settings, the case-fatality rate is as high as 25%.
- 1 out of 10 people who get Legionnaires' disease will die from the infection.



Figure 1 ([Levofloxacin], n.d.)



Figure 2 ([Levaquin], n.d)

Focus on plumbing and biofilm



Figure 1 ([Biofilm in pipe],n.d.)

CONCERNS:

- Age of piping
- Scale build up
- Biofilm buildup
- Dead legs
- Water stagnation




Figure 2 (CDC, 2025)




Figure 1 ([Dead leg], n.d.)



Figure 2 ([Dead leg], n.d.)

Dead Legs

A **dead leg** in a plumbing system refers to a section of piping that receives no or infrequent water flow.

Water Management Industry Standards


- Industry standard
 - ASHRAE Standard (2015, 2018)
- Health care
 - VHA Directive 1061 (2014)
 - CMS requirement (2017)
 - The Joint Commission
- Regulations
 - State & local



ASHRAE STANDARD 514



ASHRAE STANDARD 188



ASHRAE GUIDELINE 12





Figure 1([Drinking water], n.d.)

What is the OSHA Standard for Legionella bacteria in water?

Raw/Non-potable: not safe for human consumption and must be treated to remove impurities and contaminants.

Tap/potable water: water safe for drinking and meeting safety standards




Figure 2 ([Chlorine in water disinfection], n.d.)

Figure 1. Routine *Legionella* testing: A multifactorial approach to performance indicator interpretation*^oΔ

Concentration indicates that *Legionella* growth appears:

Uncontrolled	Poorly Controlled	Well Controlled			
≥10 CFU/mL [†] in potable water OR ≥100 CFU/mL in cooling towers	1.0–9.9 CFU/mL in potable water OR 10–99 CFU/mL in cooling towers	Detectable to 0.9 CFU/mL in potable water OR Detectable to 9 CFU/mL in cooling towers	No <i>Legionella</i> detected in a single round of testing	No <i>Legionella</i> detected in multiple rounds of testing	No <i>Legionella</i> detected in multiple rounds of testing with methods that detect viable and non-viable bacteria of any <i>Legionella</i> species

Change in concentration over time indicates that *Legionella* growth appears:

Uncontrolled	Poorly Controlled	Well Controlled			
100-fold or greater increase in concentration (e.g., 0.05 to 5 CFU/mL)	10-fold increase in concentration (e.g., 0.05 to 0.5 CFU/mL)	<i>Legionella</i> concentration steady (e.g., 0.5 CFU/mL for two consecutive sampling rounds)	No <i>Legionella</i> detected in a single round of testing	No <i>Legionella</i> detected in multiple rounds of testing	No <i>Legionella</i> detected in multiple rounds of testing with methods that detect viable and non-viable bacteria of any <i>Legionella</i> species

Extent indicates that *Legionella* growth appears:

Uncontrolled	Poorly Controlled	Well Controlled			
Detection in multiple locations AND a common source location [‡] OR Detection across many locations within a water system	Detection in a common source location that serves multiple areas OR Detection in more than one location within a water system	Detection in a few of many tested locations within a water system	No <i>Legionella</i> detected in a single round of testing	No <i>Legionella</i> detected in multiple rounds of testing	No <i>Legionella</i> detected in multiple rounds of testing with methods that detect viable and non-viable bacteria of any <i>Legionella</i> species

Type[¥] of *Legionella* (species and serogroup)
associated with Legionnaires' disease:

Highly Associated	Less Associated
<i>L. pneumophila</i> serogroup 1; Non-Lp1 <i>L. pneumophila</i> ; Presence of multiple different <i>Legionella</i> species or serogroups	Any non- <i>pneumophila</i> <i>Legionella</i> species including "blue-white" fluorescent <i>Legionella</i>

* This figure is intended for use during routine testing of potable water and cooling towers only. Due to their ability to rapidly grow and spread *Legionella*, any detection of viable *Legionella* in a hot tub or decorative fountain should prompt a response, including a review of the water management program and corrective actions. Test results are performance indicators and are not a measure of risk of human illness. This figure is not intended for use if a building or device is associated with Legionnaires' disease (LD) cases or an outbreak.

^o See "Routine testing for *Legionella*" for guidance regarding suggested response activities. Comparable results may lead to different suggested response activities when other factors are considered (e.g., if there is evidence of poorly controlled growth at a healthcare facility).

Δ Considering the type of *Legionella* identified along with other *Legionella* testing performance indicators provides a clearer picture of water system control than the results of any single indicator. For example, facility owners and operators may consider implementing immediate interventions for a healthcare facility with: A. detectable but <10 colony-forming units per milliliter (CFU/mL), B. non-Lp1 *Legionella pneumophila*, C. observed at steady concentrations, but D. detected at multiple distal locations including a central water heater.

[†] Concentrations expressed as CFU/mL are for test results generated by traditional spread plate culture methods. If other test methods are used, consult testing lab or manufacturer instructions for appropriate interpretation.

[‡] Common source location examples include water heaters, hot water returns, storage tanks, and cooling tower basins.

[¥] If a facility has a history of associated LD cases, then sequencing isolates obtained during routine testing may provide performance indicators regarding outbreak strain persistence (if that strain is detected).



321985-G

CDC Legionella Water Management Program Toolkit

- It is a step-by-step guide on how to create a water management plan
- Translates ASHRAE Standard 188 into plain language for wider audiences




Figure 1(CDC, 2025)

Waterborne Management Program: The Healthcare Statistics: 2022

- 25% of hospitals **do NOT** have a water management program
- 77% of hospitals **have NOT** implemented their water management program

Inadequate water management leads to increased risk of LD



Communication

A Methodology for Classifying Root Causes of Outbreaks of Legionnaires' Disease: Deficiencies in Environmental Control and Water Management


Benjamin R. Clappier^{1,2,*}, Jason M. Kuntz^{1,2}, Simone W. Salandy², Jessica C. Smith², Brian C. Hubbard² and John P. Szilagyi²

CDC investigations show 9 out of 10 outbreaks were caused by problems preventable with more effective water management


¹ Garrison LE et al. *MMWR*. 2016;65(22):557–61.

² Clappier BR et al. *Microorganisms*. 2021;9(1):89.

Most WMP deficiencies associated with outbreaks were due to missing or improperly implemented WMPs.



Most environmental deficiencies were due to process failure.



All the deficiencies associated with outbreaks could have been prevented by comprehensive, properly implemented water management programs.

Water management programs

**can prevent
problems**

that lead to outbreaks




Figure 1: (CDC 2024)

Partnership is the key & requires the efforts of:

- Environmental health
- Epidemiology
- Laboratory science

UConn Water Management Team



Figure 1: (Walker, 2022)

- Director of **Facilities** Engineering
- Director of **Epidemiology**
- **Infection prevention**
- Program Director of **Bone Marrow Transplant**
- Clinical Program Coordinator BMT
- **Central Sterile**
- Supervisor **Plumbing**
- Associate Prof of **Pathology & Lab Medicine**
- Supervisor **HVAC**
- Clinical Lab Supervisor of **Microbiology**
- Associate Director of Clinical Laboratory
- Accreditation and **Regulatory Affairs**
- Safety and Quality Office School of Dental
- Director of **Environmental Health and Safety**
- **Clinical Engineering**
- Director of **Physical Environment**
- Supervisor of Engineering Control Center
- **Regulatory Compliance** Office
- **Infectious Disease/Epidemiology** MD
- **MDC Water Company**

COMPLIANCE WITH CMS

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop C2-21-16
Baltimore, Maryland 21244-1850



Center for Clinical Standards and Quality/Quality, Safety and Oversight Group

DATE: June 02, 2017


Ref: **QSO-17-30- Hospitals/CAHs/NHs**
REVISED 07.06.2018

TO: State Survey Agency Directors

FROM: Director
Quality, Safety and Oversight Group (*formerly Survey & Certification Group*)

SUBJECT: Requirement to Reduce *Legionella* Risk in Healthcare Facility Water Systems to Prevent Cases and Outbreaks of Legionnaires' Disease (LD)

Water Management Plan: Assessing Building Risk



Potential Sources of Contamination

- Cooling towers and evaporative condensers
- Dialysis water and equipment
- Hydrotherapy tanks and pools
- Heating and cooling equipment
- Equipment that is connected to main water systems (such as endoscope reprocessors and dental unit water lines)

Currently Owned and Occupied on or near Farmington Campus

Building/ Area ID	Description	Gross SF	Interior SF	Address	City, ST Zip Code	Owned/ Leased	Condition	Year Built / Acq	Primary Usage	Table 5.1			Table 5.2			Table 5.3		
										Cooling Towers	Whirlpools	Ornamental Features	Multiple housing with cent hw	>10 Stories	24/7 Health care	Burn unit, Chemo, Cancer, Organ trans	Weekend Immun	Housing for 64 and older
1	MAIN BUILDING	1,773,403	1,557,071	263 FARMINGTON AVE	FARMINGTON, CT 06030	OWNED/OCC												
Area AA	ACADEMIC ADDITION	32,029	14,656				EXCELLENT	2016	EDUCATION	N	N	N	N	N	N	N	N	N
Area A	ACADEMIC	168,591	151,129				GOOD	1972	EDUCATION	N	N	N	N	N	N	N	N	N
Area B	CENTER FOR COMPARATIVE MEDICINE	54,068	45,923				EXCELLENT	1972	RESEARCH SUPPORT CLINIC	Y	N	N	N	N	N	N	N	N
Area C	CLINIC	335,935	304,034				GOOD	1975	HOSPITAL	N	N	Y	N	N	N	N	N	N
Area F	CANZONETTI	96,391	86,257				GOOD	1993	HOSPITAL	Y	N	N	Y	N	N	N	N	N
Area H	CONNECTICUT TOWER	190,093	167,786				FAIR	1975	HOSPITAL	N	N	N	Y	N	Y	N	Y	Y
Area L	BLDGL	476,138	414,417				GOOD	1972	RESEARCH	N	N	N	N	N	N	N	N	N
Area T	UNIVERSITY TOWER	420,158	372,869				EXCELLENT	2016	HOSPITAL	Y	N	N	Y	Y	Y	Y	Y	Y

Action Code	5.1	5.2	Action
A	No Y	No Y	Review if conditions change
B	1 +	No Y	Treatment plan for areas of concerns
C	No Y	1+	Treatment and management plan
D	1+	1+	Include in management plan

ASHE: Risk groups for Legionella in hospital

Low risk:

- Office areas
- Common areas

Medium risk:

- Outpatient care areas
- Outpatient surgery, PACU
- Behavioral Health
- Food & nutrition
- Cardiac Cath Lab
- Radiation Therapy
- Pharmacy
- Laboratories
- Echocardiography
- Endoscopy
- Nuclear Medicine
- PT & RT

High risk:

- Medical inpatient areas
- Surgical inpatient areas
- MICU, SICU, NICU, CCU
- L&D and newborn nurseries
- Pediatrics
- Skilled nursing facilities
- Long term acute care ventilator units

Highest risk:

- Special units caring for immunocompromised patients
- Burn units
- Oncology units
- Transplant units

Risk Assessment




UNIVERSITY TOWER			CONNECTICUT TOWER		
		MECHANICAL	N/A	MECHANICAL	
P	N/A				
7	N/A	Info Tech - Offices	LOW	7: Med/Surg/Pt Obs	
6	High	Oncology / BMT	LOW	6: Out Pat Infussion/ Sleep	
5	MED	ORTHO/SURGE	MED	5: DOC UNIT	
4	MED	MEDICAL SURVIVAL	LOW	4: Out Pat Sickle Cell	
3	MED	MEDICAL SURGICAL DIALYSIS	LOW	3: Out Pt - Neuro	
2	MED	INTERMEDIATE CARE	LOW	2: ON-CALL/OFFICES	
1	HIGH	ICU	LOW	1: PSYCH	
M	LOW	SURGERY SUPPORT/IMAGING/CAFE	LOW	M: RADIOLOGY	
G	HIGH	SURGERY	HIGH	G: NICU/MATERINTY	
B	LOW	EMERGENCY/CS	LOW	B:GI/ENDO/CT	Vacant ORs
LB	N/A	MECHANICAL	N/A	SB: MECH	

UConn John Dempsey Hospital
Legionella Risk Assessment
April 2026

Other Uconn Health Facilities:
OP – Cancer Center and Radiation
Oncology = Med/High
MSI Ors= High
All other areas reviewed and
considered Low

Water Management Diagram-University Tower


NON-POTABLE WATER SYSTEM FLOW DIAGRAM
UConn Health T Building- University Tower



Key: Backflow Preventer Water Flow Recirculating Return Flow Condensate Drainage Chilled-Water Closed Loop System

* Blue Asterisk indicates validation Legionella testing location

POTABLE WATER SYSTEM FLOW DIAGRAM
UConn Health T Building- University Tower



Key: Backflow Preventer Water Flow Recirculating Return Flow Mixing Valve Booster Pump

* Blue Asterisk indicates validation Legionella testing location

Non-Potable Water System Flow
Diagram

Potable Water System Flow
Diagram

Monitoring internal factors: WATER TESTING

Sample / Sampling Description

Date/ Time Collected: 02/02/2026 10:23 am

Collection Site: 28 Shepard Dr.

Sample Point: Quench Water System

Sample Temp. at Receipt: 4-21°C

Collected By: Matt Dalton

Collection Source: Municipal

Treatment: Quench Water System

Chilling Process: ☒ Started ☐ Not Started
Holding Times: ☒ Met ☐ Not Met

Parameter	Results	Units	Method	MCL/Range	Date and Time Tested	
Coliform	ABSENT	per 100 mL	SM9223B	ABSENT	02/02/2026	4:00 pm
<i>E. coli</i>	NEGATIVE	per 100 mL	SM9223B	NEGATIVE	02/02/2026	4:00 pm
Apparent Color	0	CU	SM2120B	15	02/02/2026	1:41 pm
Chlorides*	12.3	mg/L	E300.0	250	02/03/2026	
Free Chlorine	<0.13	mg/L	SM4500Cl-G	4	02/02/2026	1:33 pm
Hardness*	16.0	mg/L	SM2340B11	200	02/05/2026	
Iron*	0.030	mg/L	E200.7	0.3	02/05/2026	
Manganese*	0.002	mg/L	E200.7	0.3	02/05/2026	
Nitrate – Nitrogen*	0.03	mg/L	E300.0	10	02/03/2026	7:12 pm
Nitrite – Nitrogen*	<0.004	mg/L	E300.0	1	02/03/2026	7:12 pm
Odor	ND	TON	SM2150B	2	02/02/2026	1:41 pm
pH	6.70	pH units	SM4500HB	6.4-10.0	02/02/2026	1:41 pm
Sodium*	12.0	mg/L	E200.7	100	02/05/2026	
Sulfate*	<5.0	mg/L	E300.0-2.1	250	02/03/2026	
Turbidity	0.25	NTU	SM2130B	5	02/02/2026	1:41 pm

CU = Color Units MCL = Maximum Contaminant Level NTU = Nephelometric Turbidity Unit ND = none detected TON = Threshold Odor Number

Sample / Sampling Description

Date/ Time Collected: 02/02/2026 10:25 am

Collection Site: 28 Shepard Dr.

Sample Point: Quench Water System

Sample Temp. at Receipt: 4-21°C

Collected By: Matt Dalton

Collection Source: Municipal

Treatment: Quench Water System

Chilling Process: ☒ Started ☐ Not Started
Holding Times: ☒ Met ☐ Not Met

Parameter	Results	Units	Method	MCL/Range	Date and Time Tested	
Coliform	ABSENT	per 100 mL	SM9223B	ABSENT	02/02/2026	4:00 pm
<i>E. coli</i>	NEGATIVE	per 100 mL	SM9223B	NEGATIVE	02/02/2026	4:00 pm
Apparent Color	0	CU	SM2120B	15	02/02/2026	1:45 pm
Chlorides*	<5.0	mg/L	E300.0	250	02/03/2026	
Free Chlorine	<0.13	mg/L	SM4500Cl-G	4	02/02/2026	1:39 pm
Hardness*	<0.1	mg/L	SM2340B11	200	02/05/2026	
Iron*	<0.010	mg/L	E200.7	0.3	02/05/2026	
Manganese*	<0.001	mg/L	E200.7	0.3	02/05/2026	
Nitrate – Nitrogen*	<0.01	mg/L	E300.0	10	02/03/2026	7:21 pm
Nitrite – Nitrogen*	<0.004	mg/L	E300.0	1	02/03/2026	7:21 pm
Odor	ND	TON	SM2150B	2	02/02/2026	1:45 pm
pH	8.22	pH units	SM4500HB	6.4-10.0	02/02/2026	1:45 pm
Sodium*	<0.2	mg/L	E200.7	100	02/05/2026	
Sulfate*	<5.0	mg/L	E300.0-2.1	250	02/03/2026	
Turbidity	<0.14	NTU	SM2130B	5	02/02/2026	1:45 pm

CU = Color Units MCL = Maximum Contaminant Level NTU = Nephelometric Turbidity Unit ND = none detected TON = Threshold Odor Number

Control Measures-Hot Water

Water temperature is tested monthly in the control towers

Pros:

- Effective at killing Legionella
- Works quickly to kill Legionella
- ASHRAE 188 recommended

Cons

- Scalding is a concern
- Equipment longevity (scale, corrosion)
- Does not penetrate biofilm

How Water Temperature Affects Legionella




Figure 1: (Legionella in Our Water, 2023)

LEGIONELLA TESTING –performed semi annually (only on BMT unit)

Date/ Time Collected: 02/03/2026 10:45 am – 11:00 am

Collection Site: UCONN HC BMT, 263 Farmington Ave

Sample Temp. at Receipt: 13-16°C

Collected By: Matthew Dalton

Collection Source: Municipal

Treatment: N/A

Chilling Process:


☒ Started ☐ Not Started

Holding Times:

☒ Met ☐ Not Met

ID	Sample Description	<i>Legionella Pneumophila</i>	Date Tested
01	P-Sink 625	Not Detected*	02/04/2026
02	BR-Sink 625	Not Detected*	02/04/2026
03	Shower 625	Not Detected*	02/04/2026
04	P-Sink 626	Not Detected*	02/04/2026
05	BR-Sink 626	Not Detected*	02/04/2026
06	Shower 626	Not Detected*	02/04/2026
07	P-Sink 624	Not Detected*	02/04/2026
08	P-Sink 627	Not Detected*	02/04/2026
09	P-Sink 628	Not Detected*	02/04/2026
10	Main Water Supply	Not Detected*	02/04/2026

CFU = Colony Forming Units



ICE, ICE, ~~BABY~~ DEADLY

Bacteria in UPMC Ice Machine Contributed to Patient Death

Figure 1 (Staff, 2014)

HEALTH NEWS

Legionella bacteria at Syracuse hospital found in two patient sinks, ice machine

Figure 3 (Mudler, 2015)

Ice maker, sinks linked to UW Medical Center Legionnaires' outbreak; 2 dead

Figure 4 (Staff, 2016)



Figure 2 ([Dirty ice machine legionella], n.d.)



Figure 5 (Sinnerton, 2016)

Water Management External Factors:

Changes in municipal water quality



Changes in water pressure



Water main breaks



Construction

Hospital construction & renovation risk to hospitalized patients



Figure 1 (Lin et al., 2011)

- In Ohio, 11 cases of hospital-acquired Legionnaires disease were identified in patients moved to a newly constructed 12-story addition in a hospital, and 1 of those died.
- 407 cases of legionella linked to soil intensive activities resulting in 48 deaths from 2000-2014 according to a recent CDC investigation



**Water Problems: WATER MAIN
BREAKS**


2016 & 2019

Water Problems:

MDC Water pressure: 2019



Figure 1 (Fox Plumbing, 2023)



Water problems: Legionella in BMT unit (prior to the grand opening of the unit)

Legionella Detection - ID, Enumeration, & Serotyping of *L. pneumophila* plus 10 other *Legionella* species by ISO 11731:2017 Culture Method (EMSL Test Code M343 & Method MICRO-SOP-105)

Client Sample ID/Sample Location Lab Sample Number	Sample Type	Volume Submitted (mL)	Volume Filtered (mL)	Method Processed	Identification	Volume Examined (mL)	Limit of Detection (CFU/mL)	Final Results (CFU/mL)
COLD-SINK 1 - PATIENT ROOM SINK 242304588-0001	Potable	1000	1000	Concentrated	None Detected	20	0.05	ND
COLD-SINK 2 - PATIENT ROOM SINK 242304588-0002	Potable	1000	1000	Concentrated	None Detected	20	0.05	ND
HOT-SINK 1 - PATIENT ROOM SINK 242304588-0003	Potable	1000	1000	Concentrated	<i>Legionella pneumophila</i> (sero 1)	20	0.05	0.10
HOT-SINK 2 - PATIENT ROOM SINK 242304588-0004	Potable	1000	1000	Concentrated	<i>Legionella pneumophila</i> (sero 1)	20	0.05	0.05
BATH-SINK 1 - BATH-SINK 242304588-0005	Potable	1000	1000	Concentrated (Acid)	<i>Legionella pneumophila</i> (sero 1)	2	0.50	7.50
BATH-SINK 2 - BATH-SINK 242304588-0006	Potable	1000	1000	Concentrated (Acid)	<i>Legionella pneumophila</i> (sero 1)	2	0.50	0.50
SHOWER-1 - SHOWER 242304588-0007	Potable	1000	1000	Concentrated (Acid)	<i>Legionella pneumophila</i> (sero 1)	2	0.50	1.00
SHOWER-2 - SHOWER 242304588-0008	Potable	1000	1000	Concentrated (Heat)	<i>Legionella pneumophila</i> (sero 1)	20	0.05	0.15
NURSE-SINK 1 - NURSE STATION 242304588-0009	Potable	1000	1000	Concentrated	None Detected	20	0.05	ND
NURSE-SINK 2 - NURSE STATION 242304588-0010	Potable	1000	1000	Concentrated	<i>Legionella pneumophila</i> (sero 1)	20	0.05	0.05

Infection Preventionist Role

- Basic knowledge of the components of water systems
- Identify sources and modes of transmission of water borne illness
- Help develop and monitor water management plans to align with industry standards
- Invite facilities to IPC Committee to discuss water management program
- Become a member of Water Management team
- Monitor ICRA (infection control risk assessment)-
- Reporting cases to DPH cases
- Provide education and training to staff on proper water management practices to reduce the risk.



Case Definition & Reporting

- The CT DPH uses the national surveillance case definition to determine case status.
- Is reportable to the CT DPH & is a nationally notifiable disease.



Figure 1: (DPH, n.d)

CDC's role

CDC monitors Legionellosis cases using two surveillance systems at the national level:

- National Notifiable Disease Surveillance System (NNDSS)
- Supplemental Legionnaires' Disease Surveillance System (SLDSS)




Figure 1 (CDC, n.d)



Figure 2 ([Epidemiology. Health danger risk spread laboratory], 2019)

Exposure Categories Definitions



Patient spent at least one night away from home in the 14 days before symptom onset (includes nights in the state of residence, another state, or another country)

Travel Associated Case



Outbreaks of Legionnaires' disease can be difficult to detect

Figure 1 (Smith, 2024)



Criteria for a full investigation

- 1 or more cases of presumptive health-care associated legionnaire's disease at any time at the same healthcare facility
- 2 or more cases of possible healthcare-associated Legionnaire's disease within 12 months of each other at the same healthcare facility.
- When a statically significant increase in Legionnaires has been found in a defined geographic area compared against a historical background for the same geographic area

Investigations are Important for Linking Cases and Identifying Likely Sources




Figure 1 (CDC, 2025)

HOSPITAL OUTBREAK

..

When risk becomes
reality



Figure 1 ([Adorable scared baby in a white onsie in a cozy living room], 2024)

Initial steps

Confirm diagnosis & contact the local health department

Interview case-patient to determine the exposure

Environmental assessments: changes in water quality and water sampling

Implement water restrictions: no using ice machines,
no showering, no tap water-use bottled water

DPH-Enhanced surveillance plan

Instruct clinicians at the facility to evaluate patients with respiratory symptoms for pneumonia.

Order chest X-rays to confirm pneumonia.

Coordinate appropriate testing

Create and maintain line list for patients with any respiratory illness and results of any relevant testing (i.e., testing for other pathogens that may cause respiratory illness).

Maintain surveillance for at least 6 months from the time of last facility-associated case.

Environmental assessment, Facility Inspection and Water System Sampling

- Conduct a thorough building inspection to identify all potential *Legionella* sources.
 - Water-cooled, heat-transfer systems
 - Domestic water systems
 - Humidifiers and misters
 - Any water sources maintained above 20°C (68°F) and that could be aerosolized.
- Perform environmental water system sampling




Figure 1 (CDC, n.d)

Implement Controls to Prevent Additional Exposure

Controlling	Controlling exposure to Legionella during an outbreak might not require facility shutdown. Temporary provisions to isolate the affected water system can allow work to continue, and may include:
Supplying	Supplying bottled water for drinking instead of drinking from the domestic cold-water system.
Shutting	Shutting down water heaters to eliminate access to hot water in the domestic system.
Using	Using temporary cooling towers.
Utilizing	Utilizing portable heaters, air conditioners, and fans instead of the contaminated HVAC system

Water Treatment for Legionella

- Chlorine as a disinfectant
- Monochloramine
- Chlorine Dioxide
- Copper-Silver Ionization
- Ozone
- Ultraviolet Light Disinfection

Treatment will alter water quality

- >lead, copper, nitrate, nitrites, chlorite (to name a few)
- Corrosion to medical devices & equipment

When is an Outbreak Investigation Over

No new cases
following
implementation of
long-term legionella
control strategies

No detection of
legionella during
post-remediation
environmental
monitoring



Figure 1 ([Magic book], n.d.)

Although the medical case
had been solved,
Legionnaires' disease has
not been confined to the
history books

BURDEN




Figure 1 (Baker-Goering, et. al, 2021))




Figure 2 ([Dollar sign], n.d.)



Figure32 ([Danger], n.d.)

2018: USA Peak in Cases



Quick Stats - Current Filters	
Outbreaks	Illnesses
98	375
Hospitalizations	Deaths
281	34

Source: CDC





Figure 3a. Crude incidence^a rates of reported confirmed cases of Legionnaires' disease^b by jurisdiction of residence^c—NNDSS,^d United States, 2018.^{e,f}



^aCrude incidence of cases per 100,000 population (number of confirmed Legionnaires' disease cases reported that year divided by postcensal resident jurisdiction population estimate for that year times 100,000 population).

Figure 6a. Number of reported confirmed cases and deaths of Legionnaires' disease by exposure category^a—SLDSS,^b complete reporting jurisdictions,^c 2018.^d

	Cases		Deaths	
	N	%	N	CFR ^e
Exposure category	(Total = 8,764)		(Total= 719)	
Any Healthcare	1,584	18.1	156	9.8
Definite Healthcare	204	2.3	53	26.0
Possible Healthcare	1,380	15.7	103	7.5
Any Travel	1,279	14.6	35	2.7
Any Assisted or senior living	326	3.7	30	9.2
None of these	5,886	67.2	342	5.8

Figure 1 (CDC, 2025)

Seasonal pattern of Legionella in 2018 in USA

Figure 2. Number of reported confirmed cases of Legionnaires' disease^a by month^b and year^c—NNDSS,^d United States, 2018 and 2019.




Figure 1 (CDC, 2025.)




Figure 2 ([Cold drink on high temperature], n.d.)




Figure 1 Moffa et al., 2023)

Most legionella cases are sporadic

► Epidemiol Infect. 2023 Jul 28;151:e133. doi: [10.1017/S0950268823001206](https://doi.org/10.1017/S0950268823001206)

Legionellosis on the rise: A scoping review of sporadic, community-acquired incidence in the United States

[Michelle A Moffa](#)¹, [Clare Rock](#)^{2,3}, [Panagis Galiatsatos](#)^{4,5}, [Shantini D Gamage](#)^{6,7}, [Kellogg J Schwab](#)⁸, [Natalie G Exum](#)⁸,

Legionella in CT 1980-1997

(prior to the surveillance era)

Nosocomial Legionnaires Disease Associated with Exposure to Respiratory Therapy Equipment, Connecticut

ELLEN JONES, PATRICIA CHECKO, ANECIA DALTON, JOHN COPE, JAMES BARBAREE,
GEORGE KLEIN, WILLIAM MARTIN, AND CLAIRE BROOME

*Centers for Disease Control, Atlanta, Georgia 30333, and State Department of Health Services, Hartford,
Connecticut 06010*

Numerous investigators have suggested a role for potable water in outbreaks of nosocomial Legionnaires disease (LD) (1, 2, 3). An investigation of an outbreak of nosocomial LD has allowed us to extend previous observations concerning the role of contaminated potable water among immunosuppressed patients receiving respiratory therapy.

Between December 1980 and December 1982, 36 cases of nosocomial LD occurred in a 400-bed Connecticut hospital. However, only 18 of these patients had been hospitalized continuously during the 10 days before onset of illness, so only

correlated and it was difficult to evaluate them as independent variables. Further analysis of the relationship between steroids and antacids, nebulizers and steroids, and antacids and nebulizers also was limited by the small number of cases. However, examining the data in an unmatched fashion was useful in examining trends among variables.

Among those receiving steroids, antacid use increased the risk of illness (88 versus 17%) (Table 1). However, among those not being treated with steroids, antacid therapy did not appear to have an effect (20 versus 17%).

Figure 1(CDC, 1982)

1994: 12 years later-outbreak at the same hospital

Vol. 19 No. 12

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

905

A RECURRENT OUTBREAK OF NOSOCOMIAL LEGIONNAIRES' DISEASE DETECTED BY URINARY ANTIGEN TESTING: EVIDENCE FOR LONG-TERM COLONIZATION OF A HOSPITAL PLUMBING SYSTEM

Lisa A. Lepine, MD; Daniel B. Jernigan, MD, MPH; Jay C. Butler, MD; Janet M. Pruckler, BA; Robert F. Benson, MS; Grace Kim, MD; James L. Hadler, MD; Matthew L. Cartter, MD; Barry S. Fields, PhD

ABSTRACT

BACKGROUND: In 1994, a hospital reported an increase in nosocomial legionnaires' disease after implementing use of a rapid urinary antigen test for *Legionella pneumophila* serogroup 1 (Lp-1). This hospital was the site of a previous nosocomial legionnaires' disease outbreak during 1980 to 1982.

METHODS: Infection control records were reviewed to compare rates of nosocomial pneumonia and the proportion of cases attributable to legionnaires' disease during the 1994 outbreak period with those during the same period in 1993. Water samples were collected for *Legionella* culture from the hospital's potable water system and cooling towers, and isolates were sub-

P=.56); however, 3.2% of nosocomial pneumonias were diagnosed as legionnaires' disease in 1993, compared with 23.9% in 1994 (RR, 9.4; *P*<.001). In 1994, most legionnaires' disease cases were detected by the urinary antigen testing alone. MAb testing and AP-PCR demonstrated identical patterns among Lp-1 isolates recovered from a patient's respiratory secretions, the hospital potable water system, and stored potable water isolates from the 1980 to 1982 outbreak.

CONCLUSIONS: There may have been persistent transmission of nosocomial legionnaires' disease at this hospital that went undiscovered for many years because there was no active

Nosocomial Legionnaires' Disease Outbreaks Acute Care Hospitals, CT, 1980 - 1995

Hospital	Year(s)	Number of Cases		Serogroups	Source
		Confirmed	Probable		
A	1980-1982	19	18	1,4,5	Water
B	1986	2	2	1	Water
A	1994	7	13	1	Water
C	1995	4	1	3	Water

Figure 1 & 2 (Lepine, et al, 1998)

1997 and beyond...

Legionellosis surveillance in CT

- 1997: added to list of physician & laboratory reportable diseases to CT DPH & the local health department
- 1999-2021: median number cases reported annually 55 (range 14-201) cases
- 2018: highest reported cases=201



Figure 1 (Furian, 2020)




Figure 2 (DPH, 2015)



Figure 1 ([Joyful Puddle Jump], n.d)

Are Peaks in Legionnaires' Disease Linked to Increased Rainfall?

Epidemiol. Infect. (2007), **135**, 811–817. © 2006 Cambridge University Press
doi:10.1017/S0950268806007552 Printed in the United Kingdom

Increased rainfall is associated with increased risk for legionellosis

L. A. HICKS^{1,2*}, C. E. ROSE JR.³, B. S. FIELDS¹, M. L. DREES^{3,4}, J. P. ENGEL⁵,
P. R. JENKINS⁵, B. S. ROUSE⁶, D. BLYTHE⁷, A. P. KHALIFAH¹, D. R. FEIKIN¹
AND C. G. WHITNEY¹

Rainfall Is a Risk Factor for Sporadic Cases of *Legionella pneumophila* Pneumonia

Carolina Garcia-Vidal^{1,2*}, Maria Labori¹, Diego Viasus¹, Antonella Simonetti¹, Dolors Garcia-Somoza³,
Jordi Dorca⁴, Francesc Gudiol^{1,2}, Jordi Carratalà^{1,2}

¹ Department of Infectious Diseases, Hospital Universitari de Bellvitge, IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Universitat de Barcelona, Barcelona, Spain,
² REPI (Spanish Network for Research in Infectious Diseases), Madrid, Spain, ³ Department of Microbiology, Hospital Universitari de Bellvitge, Barcelona, Spain,
⁴ Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain

JOURNAL ARTICLE

It's Not the Heat, It's the Humidity: Wet Weather Increases Legionellosis Risk in the Greater Philadelphia Metropolitan Area

David N. Fisman ✉, Suet Lim, Gregory A. Wellenius, Caroline Johnson, Phyllis Britz, Meredith Gaskins, John Maher, Murray A. Mittleman, C. Victor Spain, Charles N. Haas ...
[Show more](#)

The Journal of Infectious Diseases, Volume 192, Issue 12, 15 December 2005, Pages 2066–2073, <https://doi.org/10.1086/498248>

Published: 15 December 2005 [Article history ▼](#)



(Figure 1 Law, Ryan, 2017)

Legionella is becoming more common

- Warmer temperatures/climate change
- Outdated plumbing
- More extreme weather condition (increased rainfall)
- Human error & negligence in maintaining water systems
- Aging population
- Budget constraints




Morbidity and Mortality Weekly Report (MMWR)

Two Outbreaks of Legionnaires Disease Associated with Outdoor Hot Tubs for Private Use — Two Cruise Ships, November 2022–July 2024

Weekly / October 24, 2024 / 73(42):950–954

[Print](#)

Sooji Lee, MSPH¹; Chris Edens, PhD¹; Troy Ritter, PhD²; Luis O. Rodriguez, MS²; Kara Tardivel, MD³; Natalia A. Kozak-Muiznieks, PhD¹; Melisa Willby, PhD¹; Nancy Ortiz, PhD³; Adam L. Cohen, MD¹; Jessica C. Smith, MPH¹ ([VIEW AUTHOR AFFILIATIONS](#))



HARLEM OUTBREAK SUMMER 2025



Figure 1 [NYC Legionnaires' Disease Outbreak: 2 Dead, 58 Sick-What New Yorkers Need to Know], 2025)

WORLDWIDE ISSUE

> [Lancet Microbe](#). 2025 Apr;6(4):101031. doi: 10.1016/j.lanmic.2024.101031. Epub 2024 Nov 26.

Global surge of Legionnaires' disease in 2024: urgent call for heightened awareness and preparedness

Ashutosh Pareek¹, Runjhun Singhal², Aaushi Pareek², Anil Chuturgoon³, Ranjit Sah⁴, Vasso Apostolopoulos⁵

Figure 1 (Pareek, et al, 2025)

- In Australia, Europe and the United States of America, there are about 10-15 cases detected per million population



Figure 2 ([Worldwide], n.d)



> [Lancet Microbe](#). 2025 Apr;6(4):101031. doi: 10.1016/j.lanmic.2024.101031. Epub 2024 Nov 26.

Global surge of Legionnaires' disease in 2024: urgent call for heightened awareness and preparedness

Ashutosh Pareek¹, Runjhun Singhal², Aushi Pareek², Anil Chuturgoon³, Ranjit Sah⁴, Vasso Apostolopoulos⁵



Figure 1 ([Upward trend]. n.d.)

114 cases and two fatalities linked to a cooling tower in Laverton North, Melbourne, Australia.

30 confirmed cases and two deaths in London, UK.

26 Aug. 2024

27 Sep.

20 Aug.

26 Sep.

53 cases and four fatalities linked to suspected deficiencies in building water systems in Lombardy, Italy

108 cases in New Zealand


In the summer of 2025, Legionnaires' disease has spiked, with outbreaks from New York City to Sydney



Date	Location	Cases/Deaths	Summary
Nov-Dec 2025	Orlando, Florida	14/0	Legionnaires' Outbreak in a Gym
Nov 2025	Milan, Italy	11/1	Legionella, Community Outbreak
Nov 2025	Cincinnati, Ohio	2/0	Legionella in a Hospital
Oct 2025	Bloomington, Illinois	2/0	Legionella in a Nursing Facility
Aug-Sep 2025	Marshalltown, Iowa	71/2	Legionella, Community Outbreak
June-Sep 2025	Westchester County, New York	37/2	Legionella, Community Outbreak
Jul-Aug 2025	Harlem, New York	114/7	Legionella, Community Outbreak
July 2025	London, Ontario	64/2	Legionella, Community Outbreak
Mar-Apr 2025	Sydney, Australia	12/1	Legionella, Community Outbreak

Figure 1([Recent Outbreaks from Legionella and Other Waterborne Pathogens], n.d)

UConn
Legionella
cases
reported CT
DHP
2016-2026



Legionellosis (Week 14) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending April 11, 2026

Nationally Notifiable Infectious Diseases and Conditions, United States: Weekly Tables

Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending April 11, 2026 (Week 14)

Reporting Area	Legionellosis			
	Current week	Previous 52 weeks Max †	Cum YTD 2026 †	Cum YTD 2025 †
U.S. Residents, excluding U.S. Territories	41	299	1,344	1,743
New England	3	30	69	107
Connecticut	3	12	36	50
Maine	-	2	1	2
Massachusetts	-	19	28	37
New Hampshire	-	5	4	7
Rhode Island	-	6	-	1
Vermont	-	1	-	10

Figure 1: (CDC, 2025)

It continues to silently kill claiming victims and leaving death in its wake

A cartoon in the Observer newspaper on Sunday 11 August 1985, page 19, about Legionnaires' disease after a 1985 hospital outbreak in Britain



Figure 1 (MacFarlane, et. Al, 1977)

References

- Baker-Goering, M., Roy, K., Edens, C., & Collier, S. (2021). Economic Burden of Legionnaires' Disease, United States, 2014. *Emerging Infectious Diseases*, 27(1), 255-257. <https://doi.org/10.3201/eid2701.191198>
- Bouscher, D. (2023 August 7). *CDC scientist peeved by holiday party chatter named Legionnaires' disease in 1976* [Video] . The Mercury News. <https://www.mercurynews.com/2023/08/07/video-cdc-scientist-peeved-by-holiday-party-chatter-named-legionnaires-disease-in-1976>
- Cassell, K., Gacek, P., Warren, J. L., Raymond, P. A., Cartter, M., & Weinberger, D. M. (2018). Association Between Sporadic Legionellosis and River Systems in Connecticut. *The Journal of Infectious Diseases*, 217(2), 179–187. <https://www.jstor.org/stable/26493856>
- Cassell, K., Gacek, P., Rabatsky-Ehr, T., Petit, S., Cartter, M., & Weinberger, D. M. (2019). Estimating the True Burden of Legionnaires' Disease. *American journal of epidemiology*, 188(9), 1686–1694. <https://doi.org/10.1093/aje/kwz142> Center for Disease Control and Prevention. (2023, March 23). *Legionnaire's Disease*. <https://www.cdc.gov/museum/online/story-of-cdc/legionnaires/index.html>
- Center for Disease Control and Prevention. (2025 Jan 3). *Legionella Control Toolkit*. <https://www.cdc.gov/control-legionella/php/toolkit/figure-1-legionella-control-toolkit.html>
- Center for Disease Control and Prevention. (2025, June 9). *Surveillance Report 2018-2019*. <https://www.cdc.gov/legionella/php/surveillance/surveillance-report-2018-2019.html#figure-2>
- Center for Disease Control and Prevention. (2025, May 29). *Estimate of Waterborne Disease Burden in the United States/ Waterborne Disease and Outbreak Surveillance Reporting*. <https://www.cdc.gov/healthy-water-data/waterborne-disease-in-us/results.html>
- Center for Disease Control and Prevention. (2025, Dec 1). *Legionellosis Surveillance and Trends*. <https://www.cdc.gov/legionella/php/surveillance/index.htm>
- Clopper, B. R., Kunz, J. M., Salandy, S. W., Smith, J. C., Hubbard, B. C., & Sarisky, J. P. (2021). A Methodology for Classifying Root Causes of Outbreaks of Legionnaires' Disease: Deficiencies in Environmental Control and Water Management. *Microorganisms*, 9(1), 89. <https://doi.org/10.3390/microorganisms9010089>
- Garcia-Vidal, C., Labori, M., Viasus, D., Simonetti, A., Garcia-Somoza, D., Dorca, J., Gudiol, F., & Carratalà, J. (2013). Rainfall is a risk factor for sporadic cases of Legionella pneumophila pneumonia. *PloS one*, 8(4), e61036. <https://doi.org/10.1371/journal.pone.0061036>

- Garrison, L. E., Kunz, J. M., Cooley, L. A., Moore, M. R., Lucas, C., Schrag, S., Sarisky, J., & Whitney, C. G. (2016). Vital Signs: Deficiencies in Environmental Control Identified in Outbreaks of Legionnaires' Disease - North America, 2000-2014. *MMWR. Morbidity and mortality weekly report*, 65(22), 576–584. <https://doi.org/10.15585/mmwr.mm6522e1>
- Glick, T. H., Gregg, M. B., Berman, B., Mallison, G., Rhodes, W. W., Jr, & Kassanoff, I. (1978). Pontiac fever. An epidemic of unknown etiology in a health department: I. Clinical and epidemiologic aspects. *American journal of epidemiology*, 107(2), 149–160. <https://doi.org/10.1093/oxfordjournals.aje.a112517>
- Goldhaber, Susan. (2024, Aug 13). Legionnaire's Disease: A Clear and Present Danger. American Council on Science and Health. <https://www.acsh.org/news/2024/08/13/legionnaires-disease-clear-and-present-danger-48924>
- Fisman, D. N., Lim, S., Wellenius, G. A., Johnson, C., Britz, P., Gaskins, M., Maher, J., Mittleman, M. A., Spain, C. V., Haas, C. N., & Newbern, C. (2005). It's not the heat, it's the humidity: wet weather increases legionellosis risk in the greater Philadelphia metropolitan area. *The Journal of infectious diseases*, 192(12), 2066–2073. <https://doi.org/10.1086/498248>
- Danford, Matt (2025, May 12). Ice machines spread Legionella in hospital oncology unit, prompting testing overhaul. Healio. <https://www.healio.com/news/infectious-disease/20250430/legionella-in-medical-facilities-can-spread-through-ice-study-shows>
- Hicks, L. A., Rose, C. E., Jr, Fields, B. S., Drees, M. L., Engel, J. P., Jenkins, P. R., Rouse, B. S., Blythe, D., Khalifah, A. P., Feikin, D. R., & Whitney, C. G. (2007). Increased rainfall is associated with increased risk for legionellosis. *Epidemiology and infection*, 135(5), 811–817. <https://doi.org/10.1017/S0950268806007552>
- Hingston, S. (2016, July 22). 11 Things You Might Not know About Legionnaires' Disease. City Life Philly Magazine. <https://www.phillymag.com/news/2016/07/22/legionnaires-disease-Philadelphia/>
- LaGarde, A. (1996, Nov 7). *Forensic Files-Season 1, Episode 7-Legionnaire's Disease* [Video]. Facebook. <https://www.facebook.com/watch/?v=713375380775807>
- Lee, S., Edens, C., Ritter, T., et al. (2024). Two Outbreaks of Legionnaires Disease Associated with Outdoor Hot Tubs for Private Use — Two Cruise Ships, November 2022–July 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:950–954. DOI: <http://dx.doi.org/10.15585/mmwr.mm7342a33>
- Legionnaires' Disease: Recent Updates and Insights. (2025, Aug 6). USA Tales Teller. <https://usatalesteller.com/legionnaires-disease-recent-updates-and-insights-2025/>
- Leonard, N. (2025, Sept 03). How a Philadelphia outbreak of Legionnaires' disease in 1976 led to modern-day investigations and surveillance. WHYY. <https://whyy.org/articles/legionnaires-disease-history/>

- Lepine, L. A., Jernigan, D. B., Butler, J. C., Pruckler, J. M., Benson, R. F., Kim, G., Hadler, J. L., Cartter, M. L., & Fields, B. S. (1998). A recurrent outbreak of nosocomial legionnaires' disease detected by urinary antigen testing: evidence for long-term colonization of a hospital plumbing system. *Infection control and hospital epidemiology*, 19(12), 905–910.
- Lowry, P. W., Blankenship, R. J., Gridley, W., Troup, N. J., & Tompkins, L. S. (1991). A cluster of legionella sternal-wound infections due to postoperative topical exposure to contaminated tap water. *The New England journal of medicine*, 324(2), 109–113. <https://doi.org/10.1056/NEJM199101103240207>
- Moffa, M. A., Rock, C., Galiatsatos, P., Gamage, S. D., Schwab, K. J., & Exum, N. G. (2023). Legionellosis on the rise: A scoping review of sporadic, community-acquired incidence in the United States. *Epidemiology and infection*, 151, e133. <https://doi.org/10.1017/S0950268823001206>
- New York City Health Department Provides Update on Community Cluster of Legionnaires' Disease in Central Harlem(2025, Aug 14). NYC Health. <https://www.nyc.gov/site/doh/about/press/pr2025/nyc-health-provides-third-legionnaires-cluster-update.page>
- Norman. A (2025, Sept 3). What is Legionnaires' Disease. ATI. <https://allthatsinteresting.com/legionnaires-disease>
- NYC Legionnaires' Disease Outbreak: 2 Dead, 58 Sick-What New Yorkers Need to Know. (2025, Aug 5). Fingerlakes1.com.<https://www.fingerlakes1.com/2025/08/05/legionnaires-disease-new-york-outbreak-3733567/>
- Pareek, A., Singhal, R., Pareek, A., Chuturgoon, A., Sah, R., & Apostolopoulos, V. (2025). Global surge of Legionnaires' disease in 2024: urgent call for heightened awareness and preparedness. *The Lancet. Microbe*, 6(4), 101031. <https://doi.org/10.1016/j.lanmic.2024.101031>
- Recent Outbreaks from *Legionella* and Other Waterborne Pathogens (n.d.). Lamps Water Quality Management. <https://hcinfo.com/about/outbreaks/recent>
- Sakamoto, R. (2024) Legionnaires' disease outbreak in Philadelphia and the 1976 United States presidential election. *Sociology Lens*, 37(2), 269–284. Available from: <https://doi.org/10.1111/johs.12442>
- Sanford J. P. (1979). Legionnaires' disease--the first thousand days. *The New England journal of medicine*, 300(12), 654–656. <https://doi.org/10.1056/NEJM197903223001205>
- Sinnerton, J. (2016 Jan 2). Deadly Disease on Ice. Courier Mail. <https://hydrochem.com.au/resource/how-can-ice-machines-spread-legionnaires-disease/>
- Tobin, J. O., Beare, J., Dunnill, M. S., Fisher-Hoch, S., French, M., Mitchell, R. G., Morris, P. J., & Muers, M. F. (1980). Legionnaires' disease in a transplant unit: isolation of the causative agent from shower baths. *Lancet (London, England)*, 2(8186), 118–121. [https://doi.org/10.1016/s0140-6736\(80\)90005-7](https://doi.org/10.1016/s0140-6736(80)90005-7)
- Klein. C.(2025, May 27). Remembering the Legionnaires' Outbreak. History. <https://www.history.com/articles/the-discovery-of-legionnaires-disease>
- Wolfman-Arent, A. (2021, Aug 13). How the “Grande Dame of Broad Street’ led to the discovery of Legionnaires’ disease. WHYY. <https://billypenn.com/2021/08/13/bellevue-stratford-hotel-legionnaires/>

Thank You!

Closing Remarks

